+

WO2003075765A1 - Produits de contraste biospecifiques - Google Patents

Produits de contraste biospecifiques Download PDF

Info

Publication number
WO2003075765A1
WO2003075765A1 PCT/US2003/006730 US0306730W WO03075765A1 WO 2003075765 A1 WO2003075765 A1 WO 2003075765A1 US 0306730 W US0306730 W US 0306730W WO 03075765 A1 WO03075765 A1 WO 03075765A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
sample
biomarkers
imaging
cells
Prior art date
Application number
PCT/US2003/006730
Other languages
English (en)
Inventor
Konstantin Sokolov
Brian A. Korgel
Andrew D. Ellington
Rebecca Richards-Kortum
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Priority to EP03711417A priority Critical patent/EP1487343B1/fr
Priority to AU2003213729A priority patent/AU2003213729A1/en
Priority to DE60325564T priority patent/DE60325564D1/de
Priority to CA002478083A priority patent/CA2478083A1/fr
Publication of WO2003075765A1 publication Critical patent/WO2003075765A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/411—Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
    • A61B5/418—Evaluating particular organs or parts of the immune or lymphatic systems lymph vessels, ducts or nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots

Definitions

  • the present invention relates generally to biological imaging. More particularly, it concerns methods and apparatuses for using biospecif ⁇ c contrast agents to enhance the imaging of cells. Even more particularly, it concerns using metal nanoparticles and quantum dots attached to probe molecules with a high affinity to a specific biomarker on the surface of pre-cancerous and cancerous cells to enhance the imaging of those cells.
  • Cancer is the second leading cause of death in the U.S. exceeded only by heart disease.
  • the majority of cancers are of epithelial origin. Earlier detection of pre- invasive curable epithelial neoplasia remains the best way to ensure patient survival and quality of life.
  • the American Cancer Society estimated that 1 ,200,000 people would be diagnosed with cancer in 1999, resulting in 563,000 deaths.
  • Cervical cancer is the third most common cancer in women worldwide and the leading cause of cancer mortality in women in developing countries.
  • the curable precursor to cervical cancer is cervical intra-epithelial neoplasia (CIN).
  • CIN cervical intra-epithelial neoplasia
  • Approximately 50 million Pap smears are done annually in the U.S. to screen for cervical cancer and its precursor [1]; of these, the NCI estimates 6- 7% are abnormal.
  • Mass screening of asymptomatic women with the Pap smear is considered one of the most successful public health measures in the prevention of cancer [2]; the decline in the incidence and mortality of cervical cancer over the last
  • Both screening and detection could be vastly improved by in vivo optical imaging technologies that improve, automate, and decrease the cost of screening and detection.
  • contrast could be increased in a targeted manner — i.e., if distinctive contrast agents could be associated with specific biomarkers (biospecif ⁇ c contrast agents).
  • Chemoprevention refers to. the use of chemical agents to prevent or delay the development of cancer in healthy populations or patients with precancerous tissue changes. [3,4]. Several chemoprevention trials have been carried out in patients with CIN. [3].
  • chemoprevention studies have several inherent problems.
  • a second problem is that the biopsy process itself can interrupt the natural progression of the lesion. Many times these lesions are small enough that the biopsy is the cure; frequent biopsies make it difficult to accurately assess drug response. Thus, tools to assess quantitative biomarkers that do not require biopsy could considerably improve chemoprevention studies.
  • Embodiments of this invention involve in vivo optical imaging, modern nano- chemistry, combinatorial chemistry and molecular engineering, permitting optical imaging with molecular specificity.
  • optically interrogated contrast agents based on metal nanoparticles and quantum dots are attached to probe molecules with a high affinity to a specific biomarker on the surface of pre-cancerous and cancerous cells.
  • This combination of optical imaging with cancer specific contrast agents may increase optical contrast between normal and neoplastic tissue and provide useful molecular-specific information to assist clinicians in earlier detection and monitoring of pre-cancers.
  • the techniques described here accordingly may significantly benefit health care by reducing the number of unnecessary biopsies, enabling combined diagnosis and therapy, and reducing the need for clinical expertise.
  • Techniques of this invention address some of the major shortcomings of in vivo optical imaging: low signal (especially in the case of fluorescence), low contrast between normal and diseased tissue, and lack of molecular specificity.
  • low signal especially in the case of fluorescence
  • low contrast between normal and diseased tissue and lack of molecular specificity.
  • a combination of photonic probes (e.g., metal nanoparticles and quantum dots) and cancer specific molecular probes may be used. This combination may result in contrast agents that provide bright optical signals with no or very little effects of photobleaching, enhanced contrast between normal and malignant tissue, and molecular specificity characteristic for histopathologic immunostains.
  • Embodiments of this invention may further improve optical detection and monitoring of neoplasia, providing quantitative information about biomolecular signatures of cancer in the living body. This, in turn, may reduce the number of unnecessary biopsies, enable combined diagnosis and therapy, and reduce the need for clinical expertise.
  • Using techniques described herein may lead to at least three important clinical outcomes: (1) photonic probes with increased molecular sensitivity and specificity may lead to inexpensive, improved screening strategies that can be used in the U.S.
  • photonic probes that specifically increase contrast between normal and pre-cancerous tissue may reduce the costs of detecting pre-cancers
  • photonic probes that may be quantitatively assessed without the need for biopsy may greatly facilitate monitoring of cancerous tissue in a wide range of applications, including but not limited to chemoprevention studies.
  • Optical interrogation may provide non-invasive, real-time assessment of tissue pathology, while contrast agents may give molecular specificity and selectivity.
  • the combination of these optical imaging techniques with the cancer-specific contrast agents may increase optical contrast between normal and neoplastic tissue and provide useful molecular-specific information to assist clinicians in earlier detection of pre-cancers. These innovations may significantly improve the specificity and selectivity of pre-cancer detection.
  • the techniques described herein are not limited to applications involving the analysis of pre-cancerous or cancerous tissue. Rather, the techniques may be applied to a wide range of applications including but not limited to the analysis of unpurified human fluids such as whole blood, serum, or urine for the presence of circulating cancer cells and cancer related biomarkers. Such applications may thus be used to achieve novel approaches toward a more general form of cancer screening and diagnosis.
  • characteristic as used in, for instance, “characteristic optical scattering” or “characteristic fluorescence excitation” shall be interpreted broadly to mean “distinctive” or “having a feature that helps to distinguish a thing.”
  • characteristic optical scattering brought about by a metallic nanoparticle may be distinguished from optical scattering brought about by some other matter.
  • characteristic fluorescence excitation brought about by a quantum dot may be distinguished from excitation brought about by some other matter.
  • biomarker shall be interpreted broadly to a substance expressed, produced, or associated with a cell that distinguishes the cell from other cells in a mixture of cells such as tissues, organs, fluids, biological fluids, etc.
  • the cell associated with a biomarker may distinguish cells that differ in growth state, cell lineage, stage of differentiation or de-differentiation, pathologic state (such as pre-cancerous, cancerous, neoplastic, hyperproliferative, or infected cells).
  • a biomarker may, for example, distinguish endomertial cells that are abberently localized in non-uterine tissue or identify precancerous cells within a normal tissue.
  • a biomarker may include, but is not limited to proteins, nucleic acids, lipids, carbohydrates, cellular organelles, receptors, cell surface proteins, transporters, antigen presenting complexes, and other molecules that are unique or over represented in certain cell types or growth states.
  • molecular probe shall be interpreted broadly to mean a molecule that preferentially binds a biomarker.
  • a molecular probe includes, but is not limited to a proteins, polypeptides, peptides, peptide mimetics, nucleic acids, pepto nucleic acids (PNAs), antibodies, aptamers, small molecules (folic acid or mimics thereof), growth factors, lipids, lipoproteins, glycoproteins, cabohydrates, etc.
  • FIG. 1 is a schematic diagram of in vitro selection of aptamers in accordance with embodiments of the present disclosure.
  • FIG. 2 illustrates qdots attached to neuron using a site specific antibody in accordance with embodiments of the present disclosure.
  • Brightfield (left) and fluorescence (right) images are shown.
  • the bar represents 60 ⁇ m.
  • FIG. 3 is a schematic diagram showing the integration of various aspects of embodiments of the present disclosure.
  • FIG. 4 is a UN-Nis spectra of isolated (a) and aggregated (b) metal nanoparticles in accordance with embodiments of the present disclosure.
  • FIG. 5 illustrates a biotinilated bead labeled with streptavidin particles conjugates in accordance with embodiments of the present disclosure.
  • FIG. 6 illustrates the scattering of beads with high (left) and low (right) density of metal nanoparticles in accordance with embodiments of the present disclosure.
  • FIG. 7 illustrates silica coated nanoparticles in accordance with embodiments of the present disclosure.
  • FIG. 8 is a schematic diagram showing the preparation of conjugates of nanoparticles with antibodies and aptamers in accordance with embodiments of the present disclosure.
  • FIG. 9 illustrates size-dependent luminescence of Si nanocrystals in accordance with embodiments of the present disclosure.
  • FIG. 10 shows scattering properties of gold nanoparticles.
  • FIG. 11 shows optical images of SiHa cells labeled with anti-EGFR/gold conjugates.
  • FIG. 12 shows laser scanning confocal reflectance and confocal fluorescence images of pre-cancerous and normal fresh cervical ex vivo tissue labeled with anti-
  • FIG. 13 shows transmittance and reflectance images of engineered tissue constructs labeled with anti-EGFR/gold conjugates.
  • FIG. 14 shows confocal reflectance (FIGS. 14A and 14C) and fluorescence
  • FIGS. 14B and 14D images of SiHa cells on collagen I labeled with anti-MMP-9 /gold conjugates.
  • the area in the white square in (A) is shown in more detail in (C). Arrows show polarized cells.
  • FIG. 15 shows co-localized fluorescence and reflectance laser scanning confocal microscopic images obtained from SiHa cells incubated in anti-E7 gold nanoparticle conjugates with 10% PNP. Autofluorescence due to ⁇ AD(P)H is observed in the cytoplasm, while strong backscattering due to contrast agents is seen in the nucleus.
  • Sensing cancer specific biomolecular signatures, or other specific biomolecular signatures may significantly improve screening, diagnosis and prognosis, assist in design of treatment, and facilitate monitoring of disease.
  • biomolecular signatures - such as cancer biomarkers - can only be assessed through invasive, painful biopsy.
  • techniques are divulged that combine the advantages of real-time, in vivo optical imaging with innovative, molecular specific contrast agents to provide a unique opportunity for highly selective and sensitive detection of, for instance, cancer related biomarkers in vivo.
  • optically interrogated contrast agents may be based on metal nanocrystals and quantum dots attached to probe molecules with a high affinity to a specific biomarker on the surface of epithelial cancer cells.
  • Optical interrogation may provide non-invasive real time assessment of tissue pathology, while contrast agents give molecular specificity and selectivity.
  • the combination of optical imaging techniques with cancer specific contrast agents may increase optical contrast between normal and neoplastic tissue and provide useful molecular-specific information to assist clinicians in earlier detection of pre-cancers. Accordingly, the techniques disclosed herein may significantly improve the specificity and selectivity of the detection of conditions such as pre-cancer.
  • optical methods may be limited by relatively small penetration depth of light inside a turbid human tissue (about 1.5 mm); therefore, certain aspects of this disclosure may be better suited for application to epithelial tissue.
  • the majority of cancers are of epithelial origin; hence, certain embodiments described herein find direct applicability to situations involving cancer.
  • there are several techniques that can be applied to increase penetration depth of light inside of tissue including but not limited to U.S. Patent No. 6,275,726, which is hereby incorporated by reference.
  • aspects of this invention involve concepts relating to optical imaging, contrast agents, biomarkers, and various types of probes. Therefore, it is useful to first discuss each of these topics, in turn, in a general manner. With this explanation accomplished, attention may next be focused upon the application of those and related techniques to achieve even further exemplary, and therefore non-limiting, embodiments of the present invention.
  • Optical Detection of Neoplasia Optical technologies offer the ability to image tissue with unprecedented spatial and temporal resolution using low cost, portable devices; thus, they represent an ideal approach to image early neoplasia.
  • tissue reflectance spectra provide information about the wavelength dependent scattering of tissue as well as electronic absorption bands, primarily those of oxy- and deoxy hemoglobin.
  • fluorophores include the aromatic amino acids, the co-factors NAD(P)H and FAD, which describe the tissue metabolic rate, crosslinks associated with collagen and elastin, and porphyrins.
  • optical techniques have been developed to address limitations of the Pap smear and colposcopy, the follow up test performed when a Pap smear is abnormal. [21-24]. Performance of some of these algorithms exceed that of the Pap smear and are comparable to colposcopy.
  • optical imaging techniques rely on the addition of exogenous agents to enhance intrinsic contrast.
  • Acetic acid is commonly used during colposcopy to enhance contrast between normal and diseased regions in the cervix.
  • Hypertonic saline may also be used during colposcopy for increased visualization.
  • Both of these agents result in changes in the refractive index of the cell, making them potentially useful contrast agents for confocal reflectance imaging.
  • biomolecular signatures or biomarkers can currently be assessed only through invasive biopsy and the use of quantitative immunochemical analyses in vitro.
  • researchers have worked extensively to assess cervical biomarkers, both for use in screening and diagnosis and in chemoprevention trials. [27,28].
  • a number of biomarkers of cancer progression have been identified in the cervix, including quantitative histology and cytology, PCNA, MIB-1, MPM-2, HPV viral load, EGFR, polyamines, and ploidy. [27].
  • Cervical biomarkers can be divided into several categories: cyto- and histologic markers, markers indicating altered proliferation, regulation, differentiation, and genomic instability.
  • Cytologic and histopathologic markers include nuclear features, nucleolar features, and tissue architecture. [29,30].
  • Nuclear features of interest include grade, shape, area, optical density, texture, nuclear pleomorphism, and ploidy (as estimated by DNA content). Tissue architectural measurements exploit the finding that disordered nuclei are crowded and irregular.
  • proliferation markers are more likely to be associated with premalignant and malignant tissues.
  • Proliferation can be studied with Ki-67 in frozen sections and MIB-1 (an antibody to Ki-67) and proliferating cell nuclear antigen (PCNA) in archival specimens.
  • Regulation markers include tumor suppressors, HPN viral load and oncoproteins, oncogenes, growth factors and their receptors, polyamines, and arachidonic acid. These agents in their normal states help regulate cell growth. Their measurement may provide clues to the process of carcinogenesis.
  • HPN can be quantitatively measured using PCR quantification of HPN 16 and 18 E7 mR ⁇ As.
  • tyrosine kinase subfamily includes epidermal growth factor receptor (EGFR), vascular endothelial growth factor (NEGF), platelet-derived growth factor (PDGF),
  • Nascular atypia is the hallmark of colposcopic progression of CI ⁇ to cancer.
  • Nascular growth factors have an important biologic role. Fujimoto et al [34] studied NEGF in normal cervix and all cell types of invasive cervical cancer. They observed increases in NEGF, which correlated with microvessel counts in cancers.
  • Differentiation markers include fibrilar proteins (keratins, involucrin, cornifm), adhesion molecules (cell-cell: lectins, gap junction, desmosomes; cell- substrate: integrins, cadherins, laminins, fibronectin, proteoglycans, collagen), and glycoconjugates (mucins, blood group substances, and glycolipids).
  • FIG. 1 summarizes some relevant procedures that may be used in carrying out embodiments of the present disclosure.
  • the methods of the present invention may utilize aptamers with unique or improved binding characteristics to a target that is unique to or over represented (as compared to a normal or non-target cell) in, around or on a cell of interest.
  • An "aptamer” as used herein refers to a nucleic acid that binds a target molecule through interactions or conformations other than those of nucleic acid annealing hybridization described herein. Methods for making and modifying aptamers, and assaying the binding of an aptamer to a target molecule may be assayed or screened for by any mechanism known to those of skill in the art (see for example, U.S. Patent Nos.
  • Aptamers are single- or double-stranded DNA or single-stranded RNA molecules that recognize and bind to a desired target molecule by virtue of their shapes. See, e.g., PCT Publication Nos. WO92/14843, WO91/19813, and WO92/05285.
  • the SELEX procedure described in U.S. Pat. No. 5,270,163 to Gold et al., Tuerk et al. (1990) Science 249:505-510, Szostak et al. (1990) Nature 346:818- 822 and Joyce (1989) Gene 82:83-87, can be used to select for RNA or DNA aptamers that are target-specific.
  • an oligonucleotide is constructed wherein an n-mer, preferably a random sequence tract of nucleotides thereby forming a "randomer pool" of oligonucleotides, is flanked by two polymerase chain reaction (PCR) primers.
  • PCR polymerase chain reaction
  • oligonucleotides which bind the target molecule are: (a) separated from those oligonucleotides which do not bind the target molecule using conventional methods such as filtration, centrifugation, chromatography, or the like; (b) dissociated from the target molecule; and (c) amplified using conventional PCR technology to form a ligand-enriched pool of oligonucleotides. Further rounds of binding, separation, dissociation and amplification are performed until an aptamer with the desired binding affinity, specificity or both is achieved. The final aptamer sequence identified can then be prepared chemically or by in vitro transcription.
  • the length of a random sequence tract can range from 20 to over 150 residues, and can be even longer if multiple, random oligonucleotides are combined into a single pool by ligation or other methods. [44].
  • the number of individuals in a random sequence population is typically at least 10 13 and can easily be over 10 15 . For most pools, this means that upwards of all possible 25-mers are present, and a proportionately smaller number of motifs longer than 25. Because of the redundancy of biological sequences, the sequence diversity of most random sequence pools likely rivals the sequence diversity of the Earth's biosphere.
  • Aptamers have been selected against a surprising range of targets, ranging from ions to small organics to peptides to proteins to supramolecular structures such as viruses and tissues. [42,45-48]. In particular, aptamers have been selected against a wide variety of proteins, including many nucleic acid binding proteins, such as T4
  • anti-protein aptamers seem to recognize basic patches on protein surfaces.
  • the arginine-rich motifs (ARMs) of many viral proteins are recognized by aptamers (reviewed in [51]), the phosphate-binding pockets of both kinases [52] and phosphatases, [53] and the heparin-binding sites on many surface proteins and cytokines, such as basic fibroblast growth factor [54,55] and vascular endothelial growth factor. [56,57].
  • Aptamers also seem to have an affinity for pockets or cusps on protein surfaces, such as the combining sites of antibodies [58] or the active sites of enzymes.
  • aptamers [59]. Almost all proteins have either surface pockets or basic patches (indeed, even proteins with negative pi's, such as T4 D ⁇ A polymerase, typically contain sites that can elicit aptamers). Most aptamer: target complexes have dissociation constants in the nanomolar range. Moreover, aptamers recognize their targets with high specificity, and can typically discriminate between protein targets that are highly homologous or differ by only a few amino acids. [52,60,61].
  • One embodiment is based on metal nanoparticles that can be interrogated using optical reflectance
  • the another embodiment is based on quantum dots, which can be interrogated using fluorescence. Both may be linked to aptamer-based, antibody-based, or peptide-based probe molecules, as well as other small molecules that are known to preferentially bind to proliferating cells or tissues, to provide selective labeling of, for instance, precancerous, cancerous, neoplastic, or hyperproliferative cervical epithelial cells.
  • SERS Surface enhanced Raman scattering
  • nanoshell-polymer composites were proposed as a candidate for photo thermally triggered drug delivery system [70].
  • the nanoshells consisted of a dielectric (gold sulfide or silica) core and a gold shell. [71].
  • the optical resonances of that material can be shifted from the visible to the near infrared region by changing the relative thickness of the core and the shell layers.
  • the gold nanoshells are embedded inside a polymeric matrix, their illumination at wavelengths of gold plasmon resonances results in heat transfer to the local environment. This photothermal effect may be used to optically induce drug release in an implanted nanoshell-polymer composite drug delivery material [70] .
  • gold nanoparticles have been extensively used as molecular specific stains in electron microscopy of cells and tissues. [72,73].
  • the fundamental principle of interactions between the gold particles and biomolecules, especially proteins, have been thoroughly studied.
  • Metal nanocrystals, or other highly reflective nanocrystals may be prepared with tailored optical properties.
  • the nanocrystals may be characterized, modified, and conjugated with organic and bio-molecules.
  • the prepared nanostructures may be applied for structure-functional characterization of complex biological samples such as proteins, synthetic bioactive polymers, nucleic acids, and single living cells using SERS and SEF spectroscopies. [65,68,74-79].
  • qdots quantum dots
  • These extremely small nanoparticles are in the intermediate size range between the molecular and macroscopic length scales.
  • Many interesting properties of qdots result from quantum- size confinement including their luminescence. Fluorescence emission of qdots is size dependable and can range from 400 nm to 2 ⁇ m with very narrow typical emission width of approximately 20-30 nm. [80,81].
  • Green particles were coated with methoxysilylpropyl urea and acetate groups to bind in the cell nucleus and red particles were labeled with biotin to bind to F-actin filaments pretreated with phalloidin-biotin and streptavidin. Both labels were simultaneously excited using 363 nm. The nuclear membrane was nonspecifically colored resulting in an yellow color and actin filaments were specifically stained by the red qdots.
  • the second method was based on self adsorption of mercaptoacetic acid on the surface of CdSe-ZnS qdots. [84].
  • the procedure resulted in water-soluble qdots with carboxy terminal groups which were stable in PBS buffer. Carboxygroups were used to conjugate the dots to transfe ⁇ n and a human IgG.
  • the transferrin-dot conjugates induced specific receptor-mediated activity on the surface of cervical cancer cells (Hella).
  • SK-N-SH American Type Culture Collection #HTB-11
  • SK-N-SH cells are the most prevalent human neuron studied in connection with nerve signaling. Integrin ⁇ v ⁇ (i.e., vitronectin receptor) is located on the exterior of the cell [86] and has high expression levels in the SK-N-SH cell type. [87].
  • l°Ab primary antibody
  • anti-CD51 Accurate Chemical
  • Quantum dots were covalently bound to Immunoglobin G (IgG) secondary antibodies (2°Ab) and exposed to l°Ab-labeled SK-N-SH cells (see FIG. 2). Qdots coat only the cell exterior where the integrin receptors are located. Without l°Ab tagging of the cell, IgG/CdS qdots do not bind.
  • IgG Immunoglobin G
  • 2°Ab secondary antibodies
  • the inventors have used peptide recognition sequences to attach the CdS qdots to the cell.
  • the peptide sequence, RGD The peptide sequence, RGD
  • Arg-Gly-Asp is known to bind the ⁇ v ⁇ integrin, as well as other integrins, and was chosen as the recognition molecule. [88].
  • the terminal cysteine residue was added to covalently attach the recognition group to the particle surface through exposed surface Cd atoms.
  • the three intermediate glycines serve as molecular spacers to reduce steric hindrance to binding resulting from the mercaptoacetic acid groups and the nanocrystal itself.
  • the qdots were coated with a mixture of mercaptoacetic acid and CGGGRGDS because the mercaptoacetic acid stabilizes the qdot size and prevents unwanted particle aggregation, while the peptide groups supply sites for cell surface receptor binding.
  • Antibodies It will be understood that polyclonal or monoclonal antibodies specific for a molecule that is expressed or over-expressed in a cell, tissue, or organ targeted for imaging, such as pre-cancerous, cancerous, neoplastic, or hyperproliferative cells; tissues; or organs, may be used in the practice of the described invention.
  • Embodiments may include the in vivo or in vitro imaging, detection, or diagnosis of pre-cancerous, cancerous, neoplastic or hyperproliferative cells in a tissue or organ.
  • the compositions and methods of the invention may be used or provided in diagnostic kits for use in detecting and diagnosing cancer.
  • the invention may utilize antibodies specific for proteins, polypeptides, peptides, lipids, carbohydrates, lipoproteins, or other molecules that are unique to or over represented in, on, or around pre-cancerous, cancerous, neoplastic or hyperproliferative cells in a tissue or organ.
  • Means for preparing and characterizing antibodies are well known in the art (See, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).
  • Antibodies used to detect, diagnose, identify or monitor a pre-cancerous, cancerous, neoplastic or hyperproliferative cells in a tissue or organ, as well precursors or derivatives of such cells may be generated using such standard techniques.
  • Polyclonal antibodies to an antigen generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the antigen and an adjuvant. It may be useful to conjugate the antigen or a fragment containing the target amino acid sequence or target molecule to a protein that is immunogenic in the species to be immunized, e.g.
  • a bifunctional or derivatizing agent for example maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N- hydroxysuccinimide (through lysine residues), glytaraldehyde, succinic anhydride, SOCl 2 , or Ri NCNR, where R and Ri are different alkyl groups.
  • Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
  • the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies.
  • the monoclonal antibodies of the invention may be made using the hybridoma method first described by Kohler & Milstein, Nature 256:495 (1975), or may be made by recombinant DNA methods (Cabilly, et al., U.S. Pat. No. 4,816,567).
  • lymphocytes In the hybridoma method, a mouse or other appropriate host animal, such as hamster is immunized as herein above described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen used for immunization. Alternatively, lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp.59-103 (Academic Press, 1986)).
  • a suitable fusing agent such as polyethylene glycol
  • DNA encoding a monoclonal antibody of the invention may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • the DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences, Morrison, et al., Proc. Nat. Acad. Sci. 81, 6851 (1984), or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide.
  • "chimeric" or “hybrid” antibodies are prepared that have the binding specificity of an anti-cancer, pre-cancer, or hyperproliferative cell monoclonal antibody herein.
  • non-immunoglobulin polypeptides are substituted for the constant domains of an antibody of the invention, or they are substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for a first antigen and another antigen-combining site having specificity for a different antigen.
  • Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents.
  • immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond.
  • suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate.
  • the antibodies of the invention typically will be labeled with a detectable moiety (optically interrogated moiety).
  • the detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal when optically interrogated.
  • the detectable moiety is a optical contrast agent, such as a metal or semiconductor nanoparticle.
  • the detectable moiety may be a gold, silver, composite, silicon nanoparticle.
  • any method known in the art for separately conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter, et al., Nature 144:945 (1962); David, et al., Biochemistry 13:1014 (1974); Pain, et al., J. Immunol. Meth. 40:219 (1981); and Nygren, J. Histochem. and Cytochem. 30:407 (1982).
  • a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import” variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321, 522-525 (1986); Riechmann et al., Nature 332, 323-327 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.
  • humanized antibodies are chimeric antibodies (Cabilly, supra), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
  • humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
  • humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences.
  • Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
  • Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e. the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved.
  • the CDR residues are directly and most substantially involved in influencing antigen binding.
  • Human monoclonal antibodies can be made by the hybridoma method.
  • transgenic animals e.g. mice
  • transgenic animals e.g. mice
  • J H antibody heavy chain joining region
  • transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge.
  • Jakobovits et al. Proc. Natl. Acad. Sci. USA 90, 2551-255 (1993); Jakobovits et al, Nature 362, 255-258 (1993).
  • the phage display technology (McCafferty et al., Nature 348, 552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro, from immunoglobulin variable (V) domain gene repertoires from unimmunized donors.
  • V immunoglobulin variable
  • antibody N domain genes are cloned in-frame into either a major or minor coat protein gene of a filamentous bacteriophage, such as Ml 3 or fd, and displayed as functional antibody fragments on the surface of the phage particle.
  • the filamentous particle contains a single-stranded D ⁇ A copy of the phage genome, selections based on the functional properties of the antibody also result in selection of the gene encoding the antibody exhibiting those properties.
  • the phage mimics some of the properties of the B-cell.
  • Phage display can be performed in a variety of formats; for their review see, e.g. Johnson, Kevin S. and Chiswell, David J., Current Opinion in Structural Biology 3, 564-571 (1993).
  • Several sources of N-gene segments can be used for phage display.
  • the heavy or light chain N domain gene of rodent antibodies obtained by phage display technique is replaced with a repertoire of human N domain genes, creating rodent-human chimeras. Selection on antigen results in isolation of human variable capable of restoring a functional antigen-binding site, i.e. the epitope governs (imprints) the choice of partner.
  • a human antibody is obtained (see PCT patent application WO 93/06213, published Apr. 1, 1993).
  • this technique provides completely human antibodies, which have no framework or CDR residues of rodent origin.
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. One of the binding specificities is for a first antigen and the other one is for a second antigen.
  • bispecific antibodies are based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (Millstein and Cuello, Nature 305, 537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of 10 different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product yields are low. Similar procedures are disclosed in PCT application publication No.
  • Heteroconjugate antibodies are also within the scope of the present invention.
  • Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (PCT application publication Nos. WO 91/00360 and WO 92/200373; EP 03089). Heteroconjugate antibodies may be made using any convenient cross-linking methods. Suitable cross-linking agents are well known in the art, and are disclosed in U.S. Pat. No. 4,676,980, along with a number of cross-linking techniques.
  • Antibody Conjugates Antibody conjugates in which an antibody that preferentially or specifically binds pre-cancerous, cancerous, neoplastic, or hyperproliferative cell(s) is linked to a detectable labeling or contrast agent may also be used in certain embodiments of the invention. Diagnostic antibody conjugates may be used both in vitro diagnostics, as in a variety of immunoassays, and in vivo diagnostics, such as in imaging technology as described herein. Certain antibody conjugates include those intended primarily for use in vivo, where the antibody is linked to a optically interrogated agent.
  • the covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules.
  • Many bivalent or polyvalent agents are useful in coupling protein molecules to other particles, nanoparticles, proteins, peptides or amine functions.
  • Examples of coupling agents are carbodiimides, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents that may be used. In preferred embodiments, it is contemplated that one may wish to first derivatize the antibody, and then attach the contrast agent to the derivatized product.
  • cross-linking agent As used herein, the term "derivatize" is used to describe the chemical modification of the antibody substrate with a suitable cross-linking agent.
  • cross-linking agents for use in this manner include the disulfide-bond containing linkers SPDP (N- succinimidyl-3-(2-pyridyldithio)propionate) and SMPT (4-succinimidyl-oxycarbonyl- ⁇ -methyl- ⁇ (2-pyridyldithio)toluene).
  • a library of probe molecules for cancer specific targets associated with pre-cancer/cancer cells may be created and characterized, using molecular engineering and combinatorial chemistry approaches.
  • Contrast agents may be made based on metal nanoparticles for in vivo reflectance imaging.
  • the agents may include two major parts: optically interrogated labels - metal nanoparticles - and probe molecules specific for cancer biomarkers.
  • the optical properties of these labels may be synthesized and tailored, and conjugation chemistry may be used to couple labels and probe molecules.
  • Contrast agents may be made based on quantum dots for in vivo fluorescence imaging. These agents may contain quantum dot particles as optically interrogated labels and probe molecules specific for cancer biomarkers. The optical properties of these labels may be synthesized and tailored, and conjugates may be made with probe molecules.
  • molecular specific contrast agents for pre-cancer detection may be validated in at least two biological models. Suspensions of normal, pre-cancerous, and cancerous cervical epithelial cells may be used to assess relative binding efficiencies of contrast agents. Additionally, using three- dimensional, tissue phantoms containing multiple layers of epithelial cells atop a stroma, marker penetration and binding in model systems of normal, pre-cancerous and cancerous epithelial tissue may be examined.
  • the contrast agents and optical imaging techniques may be tested in living normal and neoplastic cervical tissue.
  • An ideal organ culture system of normal and pre-cancerous cervix may be used. Biopsies of normal and neoplastic cervix may be obtained, and transverse sections may immediately be prepared and maintained as an organ culture. Both types of contrast agents may be applied and interrogated to determine relative binding efficiency and penetration throughout the epithelium in living human cervical tissue.
  • FIG. 3 illustrates a general embodiment showing the integration of interdisciplinary groups to make photonic probes and contrast agents for highly sensitive and selective detection of, for instance, pre-cancers in vivo.
  • the approaches of combinatorial chemistry may be used to make a library of aptamer molecules specific for biomolecular targets on the surface of cervical cancerous and pre-cancerous cells. Aptamers exhibiting antiproliferative and antiangiogenic activity may be used. Well- established cervical cell lines at different stages of cancer development may be used.
  • Photonic probes based on quantum dots and metal nanoparticles may be made. They may utilize custom-made aptamers or existing antibodies for well-known cancer biomarkers currently used in clinical histopathology.
  • the developed conjugates may be used as molecular specific contrast agents using optical microscopy and spectroscopy.
  • the cervical cancer cell lines, three-dimensional tissue phantoms, and fresh cervical tissue slices may all be used for imaging, testing, and/or validation.
  • Experiments with all three biological systems representing properties of normal and neoplastic cervix at different levels of complexity may be used, if necessary, to assess and refine the performance and detection scheme for the contrast agents.
  • This refinement may include preparing bio-engineered aptamers with high affinity to cancer specific targets, tailoring optical properties of metal nanoparticles and quantum dots, optimizing conjugation procedures, and/or generating optimal imaging geometries.
  • Recent advancement in combinatorial chemistry provide an excellent tool for rapid screening of huge populations of biomolecules to find molecules with the best binding properties and selectivity to a specific target including whole cells.
  • one may use chemically engineered binding species based on short nucleic acid sequences (aptamers) to create molecules with improved selectivity to pre-cancerous and cancerous cells as compared to the existing antibodies.
  • aptamers short nucleic acid sequences
  • aptamers have previously been selected against cellular and organismal targets. For example, it has proven possible to use human red blood cell membranes as a target for the selection of single-stranded DNA aptamers. Several species of ssDNA were isolated that recognize distinct targets within the membranes. [89]. In addition, aptamers have been selected against whole African trypanosomes. Three classes of RNA were selected that bind with high affinity to a protein within the flagellar pocket of the parasite. [90].
  • oligonucleotides may be generated that contain a random sequence core that spans 60 residues and flanking regions that allow PCR amplification and in vitro transcription. Following amplification of the nascent
  • RNA molecules may be transcribed that contain 2' fluorinated pyrimidines.
  • the presence of 2' modified residues has been shown to substantially stabilize nucleic acids against endogenous nucleases or other perturbants.
  • RNA molecules containing 2' modified pyrimidines have previously been stable for days in sera and urine. [91].
  • RNA libraries may be gel-purified and directly used for selection. Roughly 100 micrograms (ca. 10 15 different sequences) may be applied to each of the target cell lines. Following the equilibration of binding species on the cell surfaces, non-binding or weakly binding species may be washed off using PBS. Binding species may be eluted by homogenizing the cells with detergent. While this procedure of course releases cellular nucleic acids, many of those may be destroyed by endogenous nucleases, may not be amplifiable with particular primer sets, and even if they are amplifiable may not be of the same size as the nucleic acid pool. Those aptamers in the extract may be directly amplified by reverse transcription and the polymerase chain reaction.
  • Products of the correct size may be gel-isolated and used to transcribe the sieved RNA population for the next round of selection.
  • radiolabel alpha-32P ATP
  • the fraction of radioactive RNA that binds to a given cell line may be followed by scintillation counting.
  • a relatively small fraction of the population may bind to cells in the early rounds of selection, but this fraction may progressively increase during the course of the selection.
  • the procedures described above may be used to identify aptamers that bind to a given cell line. Those having skill in the art will recognize that any number of different cell lines may be targeted.
  • the following cell lines may be focused upon: two cervical cancer cell lines (HeLa and SiHa), one HPN infected cell line (TCL-1), and a normal cervical primary culture from Clonetics (CrEC-Ec).
  • HeLa and SiHa two cervical cancer cell lines
  • TCL-1 HPN infected cell line
  • CrEC-Ec a normal cervical primary culture from Clonetics
  • a coupled negative, positive selection may be employed.
  • the R ⁇ A population may be mixed with the parental, non-transformed line, CrEC-Ec, and those R ⁇ A species that do not bind to this cell line, or that are removed by the initial PBS washes, may be amplified.
  • This delimited population may then be added to either the pre-cancerous (TCL-1) or cancerous (HeLa or SiHa line), and those R ⁇ A species that now bind may be selectively amplified.
  • Multiple rounds of coupled negative and positive selection may yield aptamers that bind to proteins or epitopes specific to transformed cells. Sequence comparisons within and between these families may aid in identifying which residues, motifs, and secondary structural features are most significant for binding. Based on such comparative results, a series of minimal aptamers may be readily synthesized and assayed for their ability to bind to cells. Those minimal aptamers that show the best binding characteristics may be selected.
  • aptamers with terminal functional groups may be synthesized to facilitate conjugation of the aptamers with nanoparticles.
  • phosphoramidite reagents known in the art that can be introduced into the synthesis so that upon completion there are either alkyl amino or alkyl thiol groups at the 5' or 3' ends of the synthetic nucleic acid.
  • a potential problem in targeting cancer related biomarkers to screen for and detect neoplastic changes lies in the fact that many of the biomarkers are only overexpressed in tumors. It implies that they are also present in normal tissue and their amount increases with cancer development.
  • Embodiments of this disclosure involve a novel detection scheme that provides enhanced contrast between normal and malignant tissue.
  • One concept of these techniques is based on changes in optical properties of metal (or any other highly reflective) nanoparticles when they form closely spaced assembles. When gold or silver nanoparticles are brought in close vicinity, their plasmon resonances interact with each other. The interaction results in a red shift of plasmon resonances of particles' assemblies as compared to the individual particles (see FIG. 4).
  • the conjugates of metal nanoparticles with probe molecules specific for cancer related biomolecular targets may be allowed to interact with tissue and then the excess of the unbound contrast agents may be washed. Closely spaced assemblies of metal nanoparticles may be formed on the surface of neoplastic cells due to high concentration of biomarkers on their surface, while only individual particles spaced further apart may be present on normal cells. In this situation, imaging with a wavelength optimized for spectral properties of the assemblies may provide enhanced contrast between normal and neoplastic tissue.
  • the inventors have conducted an experiment with biotinilated polystyrene beads labeled with conjugates of silver particles with streptavidin. Beads with a high density (see FIG. 5) and a low density of silver particle conjugates were prepared and placed on the surface of a quartz prism. Then the beads were excited using 514.5 nm wavelength of Ar+ laser in total internal reflection mode. For illustration purposes, the sensitivity of the detector was reduced so that scattering from the beads with low density of silver conjugates would not be seen (see FIG. 6). As can be seen, the beads with closely spaced assemblies of silver particles exhibit dramatic scattering while the beads with just a few particles on the surface are not visible.
  • gold and/or silver nanoparticles may be used.
  • Each of these materials has their own advantages and disadvantages. It has been reported that silver particles exhibit higher extinction coefficients and provide higher enhancements of the local electromagnetic field and of other effects associated with optical excitation of surface plasmon resonances. [92]. However, silver particles are not as stable and not as biocompatible as gold nanoparticles. This issue can be addressed by encapsulating silver particles inside an inert material. For this purpose, a silica coating may be used (see FIG. 7). [68]. This coating stabilizes particles in high ionic strength solutions and provides a well-characterized surface for chemical immobilization of biomolecules.
  • Gold and silver colloidal particles may be prepared from chloroauric acid (HAuCl 4 ) and silver nitrate (AgNO ) respectively by using a variety of reducing agents including phosphorous, [93] ascorbic acid, [94] sodium citrate, [95-97] borohydrate. [64,94].
  • sodium citrate may be primarily used.
  • Highly uniform gold colloids with particle sizes ranging from about 10 nm to ca. 100 nm may be prepared using sodium citrate reduction of chloroauric acid. [95]. This colloid exhibits a single extinction peak ranging from 500 nm to about 540 nm depending on the size of the particles (see FIG. 4).
  • Sodium citrate reduction of silver nitrate results in a colloidal solution with about 35 nm diameter silver particles and a single peak at approximately 410 nm. [96,97].
  • the distribution of silver particles is significantly broader as compared to gold particles; however the procedure is highly reproducible from one preparation to another.
  • Silver particles with narrower distributions and different mean diameters may be prepared using a starter hydrosol with small silver particles that provides nucleation centers for growth of bigger silver colloid. [94]. In different embodiments, any of several standard, well-established procedures may be used in conjunction with the production of silver particles.
  • Positions of surface plasmon resonances of gold and silver may be significantly altered by using nanocomposite materials described in, for instance, [70,71].
  • the materials include a dielectric optically inert core particle and an optically active gold shell and can be prepared in a variety of sizes and in a highly uniform fashion.
  • one may use the methods developed by Dr. N. J. Halas and Dr. J. L. West from Rice University in this regard.
  • FIG. 8 illustrates one embodiment for the preparation of conjugates of gold particles with cancer specific probe molecules.
  • probe molecules may be used: well established antibodies for molecular biomarkers of cancer and aptamers specifically developed for cancer cells. Aptamers with antiangiogenic activity may be used. Such aptamers may be used to make conjugation chemistry with the metal particles for these type of molecules. For antibodies, conjugation protocols developed to prepare gold immunostains for electron microscopy may be used. [72,73].
  • a second conjugation strategy for antibodies may include preparation of biotinilated antibody molecules and their consequent interaction with streptavidin/gold conjugates (see FIG. 8). This approach takes advantage of strong biospecific interaction between biotin and streptavidin and a well- developed protocol for immobilization of streptavidin on gold particles. [98].
  • aptamer molecules may not be directly adsorbed on the gold surface because that could significantly change their conformation and therefore lead to loss of binding properties.
  • Aptamers with thiol terminated alkyl chains may be directly attached to the surface of gold particles similar to the procedures described in [69] for preparation of DNA probes.
  • conjugation procedure one may use a mixture of thiol terminated aptamers and relatively small mercaptoacetic molecules to avoid high density immobilization of the aptamers (see FIG. 8).
  • the immobilization of antibodies and thiol terminated aptamers on silver particles may be accomplished using the strategies known in the art.
  • the silver conjugates do not have the same stability and shelf life as the gold conjugates; however, in one embodiment they may be used to evaluate the silver based contrast agents. If silver particles are well suited for a particular application, one may use the conjugation protocols for silica capped silver particles (see FIG. 8).
  • the silica layer may be formed using tetraethyl orthosilicate (TEOS) and the procedure described in detail in [68].
  • silanization reagents are available to introduce functional groups to silica surface for subsequent immobilization of proteins, [99] nucleic acids including aptamers, [100-102] etc. It was shown that binding properties of aptamers are preserved after immobilization on glass cover slides [101] and silica microspheres. [102].
  • the unique fluorescence properties of quantum dots may be used to make multi-color contrast agents for fluorescence imaging in vivo.
  • a variety of semiconductor nanocrystals, or quantum dots (qdots), with relatively high quality optical properties may be produced using solution-phase methods. [81,103,105].
  • the nanocrystal preparations should yield nanocrystals with a relatively tight size distribution (i.e., a size distribution sufficient to eliminate inhomogeneous broadening of the optical and electronic properties), crystalline cores with few compositional and structural defects, and well-passivated surfaces.
  • Particles can be functionalized with either hydrophobic (i.e., alkanes) or hydrophilic (carboxyl or amine groups for example) moieties.
  • the nanocrystals are sufficiently stable that, once made, chemistry can be done to their surfaces.
  • quantum dots may be synthesized using previously published methods.
  • carboxyl-stabilized CdS nanocrystals may be synthesized by a ⁇ ested precipitation at room temperature in an aqueous solution using mercaptoacetic acid as the colloidal stabilizer.
  • Nanocrystals may be prepared from a stirred solution of CdCl 2 (1 mM) in pure water. The pH may be lowered to 2 with mercaptoacetic acid, and then may be raised to 7 with concentrated NaOH. Then, Na 2 S 9 H 2 O may be added to the mixture.
  • chemical synthetic methods for Si nanocrystals with size- tunable photoemission color may be used (see FIG. 9). Such methods yield surface- passivated Si nanocrystals that exhibit relatively high photoemission quantum yields ( ⁇ 23%) and discrete optical transitions in the absorbance spectra, indicative of size- monodisperse samples. [105]. High resolution transmission electron microscopy
  • Both CdS and Si have strong affinity to thiols; therefore, aptamers with thiol terminated groups can be directly adsorbed on the qdots using the approach described for metal nanoparticles.
  • a variety of functional groups e.g., carboxy
  • cross-linking agents e.g., ethyl-3-(dimethylaminopropyl)carbodiimide
  • the qdots can be also encapsulated by a silica layer and then the reaction outlined on FIG. 8 may be applied for immobilization.
  • testing techniques and issues relating, at least in part, to forms of testing that may be used in conjunction with one or more embodiments of the present disclosure.
  • Such techniques may, for example, allow for an assessment of the outcome of different immobilization protocols and/or simply verify that a study is proceeding as expected or desired.
  • a reflectance spectrometer may be used to measure scattering of cells and tissue slices.
  • the range of nanoparticle optical parameters achievable with existing preparation methods may be determined to identify excitation/collection geometries that can be used for in vivo imaging.
  • the optical properties of bare nanoparticles, particles capped with a silica layer or mercaptoalkyl molecules, and particles conjugated with biomolecules may be compared.
  • Immobilization of biomolecules on nanoparticles may be verified using at least three different techniques: UN-Nis spectroscopy (qdots, metal particles), anisotropic fluorescence spectroscopy (qdots), and conjugation assays.
  • UN-Nis spectra of conjugates may exhibit absorption spectra characteristic for both antibodies and particles; controls will have only absorbance peaks of nanoparticles. Heavier conjugates may have slower rotation as compared to bare qdots that will result in higher anisotropy in their fluorescence.
  • Conjugation assays may also be carried out, where purified target molecules which specifically bind to probe molecules attached to nanoparticles may be added to a suspension of probe/nanoparticles conjugates.
  • Biocompatibility of the contrast agents disclosed herein may be a very important issue for in vivo applications. While it has been widely recognized that gold and, probably, Si based materials are inert with respect to biological tissue and are biocompatible (especially, gold), there are some concerns regarding silver and most semiconductor based materials. To address this issue, one may use silica capped CdS and silver nanocrystals. Silica is considered to be a biocompatible material except for the lung, where it can cause silicoses. In one embodiment, a topical application of the contrast agents to cervical epithelium may be used. It is not anticipated that nanoparticles can penetrate inside the human body through layers of epithelial cells, basal membrane, and stroma.
  • contrast agents may be applied to the model system by mixing (cell suspensions) or by topical application (RAFT cultures and fresh tissue slices) and may be allowed to interact with their specific targets.
  • the incubation may be performed at the temperature characteristic for, for instance, the cervix (37°C).
  • the contrast agents may be added in a solution formulated to prevent nonspecific binding of the probe molecules to the epithelial cells.
  • High relative concentrations of "non-specific" proteins such as bovine serum albumin (BSA) are commonly used for this purpose.
  • BSA bovine serum albumin
  • To determine non-specific binding one may use "bare” (without attached probe molecules but with capping layers) qdots and metal nanoparticles as well as particles with attached biomolecules which do not specifically bind to cervical epithelial cells
  • probe molecules e.g., BSA
  • BSA BSA
  • Suspensions of at least two cervical cancer cell lines may be used, one transformed, HPN infected cell line (TCL-1), and a normal cervical primary culture from Clonetics (CrEC-Ec). Quantitative comparison of binding of different contrast agents to the cell lines may be carried out. Such experiments may identify or confirm the best contrast agents for discrimination between normal, pre-cancerous, and cancerous cervical cells.
  • a combination of qdots based contrast agents of different sizes may be evaluated to improve detection of neoplastic cells in multicolor imaging strategies with a single excitation frequency (or multiple excitation frequencies).
  • Excitation/emission wavelengths for fluorescence imaging with qdots and excitation wavelengths for reflectance imaging with metal nanoparticles may be optimized to provide the best contrast between normal and abnormal cells, to provide adequate penetration of the cervical epithelium and to match small, inexpensive laser diode or LED sources.
  • fluorescence qdots
  • UN-Nis spectroscopy metal nanoparticles
  • Scattering from cells and their relatively quick sedimentation in solution can significantly interfere with quantitative measurements.
  • optical properties of particles can be altered as a result of binding. Therefore, one may centrifuge labeled cells and then measure the particles remaining in solution.
  • the amount of bound agent may be determined based on the decrease in fluorescence and/or absorption.
  • Biocompatibility of the contrast agents may also be addressed by performing standard cytotoxicity assays. Labeled cells may be grown using standard cell culture techniques to address possible long term effects of the contrast agents on the cells.
  • Tumor cells, stromal fibroblasts, and endothelial cells may express a set of genes in situ that only partially overlaps the set expressed by each cell type in isolation from the other in primary cultures.
  • Organotypic (RAFT) cultures have been developed initially for skin and then adapted for a variety of epithelial cancers as an approach to provide the three dimensional growth including epithelial cell-cell interactions that are major features of solid carcinomas. The method is based on the growth of epithelial cells at the air-liquid interface on top of a collagen gel containing fibroblasts (hence the name RAFT cultures for floating on the liquid phase).
  • This organ culture provides conditions that preserve tissue architecture, growth, and function. It can be prepared with different cell layers, different cell types and can be analyzed as a tissue without restrictions involved in obtaining actual surgical specimens from patients or volunteers. RAFT cultures are also more reproducible than tissues obtained from different individuals.
  • This biological model of the epithelium may also provide an opportunity to measure the depth of penetration of the contrast agents through multiple layers of epithelial cells and to optimize binding kinetics before undertaking more difficult and resource-consuming experiments with human tissue samples. The same optical microscopic approaches as in the case of cells may be used.
  • the contrast agents may be tested using a model system that most closely resembles living human epithelial tissue - fresh tissue slices. Dr. Richards-Kortum, Follen and Lotan have recently explored this model system to explore the biological basis for differences in the autofluorescence of normal and neoplastic cervix. [108,109].
  • To prepare fresh tissue slices cervical biopsies may be obtained, and biopsies may be immediately placed in chilled culture medium, and then embedded in agarose.
  • a Krumdieck Tissue Sheer may be used to obtain transverse, 200 ⁇ m thick fresh tissue slices, which can be maintained alive in culture for 7-10 days. Experiments with contrast agents may be performed within 1.5 to 5 hours of biopsy.
  • the tissue slices can remain in culture medium during the imaging, and an image of a field of medium may be collected as a control. Following fluorescence microscopy, 4 ⁇ m sections may be made for histological evaluation and may be read by, for instance, a board certified pathologist to provide a diagnosis.
  • contrast agents may be topically applied to the biopsy prior to preparation of tissue slices. Such studies allow one to evaluate the penetration depth of contrast agents inside the human epithelium.
  • contrast agents may be applied to prepared tissue slices. In this case, one may assess the binding profile of different contrast agents throughout the whole thickness of epithelium. Contrast between normal, pre-cancerous and cancerous lesions in living cervical tissue may be determined. The best combinations of antibodies and/or aptamers labeled with qdots and metal particles for discrimination of pre-cancerous and cancerous lesions may be identified or confirmed.
  • gold bioconjugates for vital imaging of pre-cancers is demonstrated using cancer cell suspensions, three-dimensional cell cultures, and normal and neoplastic fresh cervical biopsies.
  • gold conjugates can be delivered topically for imaging throughout the whole epithelium.
  • These contrast agents may extend the ability of vital reflectance microscopies for in vivo molecular imaging. They may enable combined screening, detection and therapy of disease using inexpensive imaging systems; such tools may allow mass screening of diseases such as cancer in resource- poor settings.
  • Non-invasive diagnostic methods are especially needed for the screening of large populations for the identification of high risk individuals who can then be followed up frequently and/or enrolled in chemoprevention trials.
  • OCT optical coherence tomography
  • RCM reflectance confocal microscopy
  • the resulting histologic-quality images can identify and monitor neoplastic changes in epithelium.
  • endoscope-compatible fiber optic OCT and RCM systems have been developed to image tissue microanatomy in vivo in near real time. These systems are portable and inexpensive compared to other high resolution imaging technologies such as MRI microscopy; as such they are ideally suited for early screening and diagnosis of superficial disease.
  • Tissue reflectance is produced by refractive index mismatches; sources of contrast in OCT and RCM images include structures with increased refractive index such as mitochondria, nuclear chromatin and melanin.
  • Non-specific contrast agents such as acetic acid, can perturb the nuclear refractive index distribution increasing the ability to visualize cellular anatomy.
  • OCT and RCM provide images of tissue microanatomy, their ability to image molecular changes associated with carcinogenesis is limited.
  • colloidal gold of various sizes was prepared using citrate reduction of chloroauric acid (HAuCl 4 ) according to the method described in Frens, G. (1973) Nature Physical Science 241, 20-22, which is incorporated by reference.
  • HEPES buffer pH 7.4
  • anti- EGFR monoclonal antibodies host mouse, Sigma
  • Polyethyleneglycol (PEG, MW 20,000, Sigma) was added to the mixture up to a final concentration of 0.2 mg/mL and the solution was centrifuged twice at 5000 rpm for 2 hours to wash unbound antibodies. After the second wash the pellet was resuspended in phosphate buffered saline.
  • SiHa cells were grown inside tissue culture flasks covered with collagen type I (Roche) in DMEM plus 5% FBS at 37°C under 5% CO 2 .
  • Cells were harvested using 1 mg/mL collagenase (Roche) in phosphate buffered saline at 37°C for approximately 20 minutes, or until the collagen substrate was entirely disassociated, and were washed in DMEM.
  • the cell suspension was labeled with gold conjugate at room temperature for ca. 30 minutes on a shaker to prevent sedimentation.
  • the labeled cells were placed on top of a microscope slide coated with gelatin to eliminate background scattering from the glass substrate during reflectance imaging.
  • a suspension of epithelial cells was spun down and a very small amount of buffered collagen type I solution (3 mg/ml) was added to the pellet.
  • the mixture was transferred to 6.5 mm Elisa plate wells and allowed to gel at 37°C for 20 minutes. The volume of the mixture was adjusted to form gels with thickness between 400 and 600 ⁇ m.
  • the gel with embedded cells was kept in DMEM culture medium plus 5% FBS for 24-48 hours. During this time the cells continued to grow resulting in formation of a highly dense structure consisting of multiple layers of epithelial cells.
  • the contrast agents were added on top of the tissue phantoms in 10% polyvinyl pyrrolidone (PNP) solution in PBS or in pure PBS. After incubation for ca.
  • PNP polyvinyl pyrrolidone
  • the wavelength dependence of light scattering was measured using the optical set-up described in Sokolov, K., Drezek, R., Gossage, K., & Richards-Kortum, R.
  • the series of through focus confocal images were acquired using Zeiss Leica inverted epi-fluorescence/reflectance laser scanning confocal microscope with a 40X oil immersion objective or a 10X objective.
  • the excitation was provided by a Kr/Ar mixed gas laser.
  • FIGS. 10-13 Corresponding figure legend are as follows:
  • FIG. 10 is a diagrammatic representation of FIG. 10
  • FIGS. 10A and 10B compare scattering of gold particles and polystyrene beads of approximately the same diameter.
  • FIG. 10A suspensions of gold particles (left) and the polymeric spheres
  • FIG. 10B shows the wavelength dependence of visible light scattering by the polystyrene spheres and the gold nanoparticles. The spectra were obtained from suspensions with the same concentration of metal and polymeric nanospheres.
  • FIG. 10C compares scattering of isolated and closely spaced (agglutinated) conjugates of 12 nm gold nanoparticles with monoclonal antibodies for epidermal growth factor receptor (EGFR). Polyclonal antibodies specific for mouse IgG (Sigma) were added to induce agglutination of the conjugates.
  • EGFR epidermal growth factor receptor
  • FIG. 11 High (FIGS. 11 A-l ID) and low (FIGS. 11G-11I) resolution optical images of
  • SiHa cells labeled with anti-EGFR/gold conjugates are shown.
  • Non-specific labeling using gold conjugates with BSA is shown in FIGS. HE and 1 IF.
  • FIGS. 11 A and 11B the focal plane is at the top of the cells.
  • FIGS. 11C and 11D the middle cross-section of the cells is in focus.
  • the confocal reflectance and transmittance images were obtained independently and then overlaid. Reflectance images were obtained with 647 nm laser excitation.
  • the scale bar is ca. 20 ⁇ m (FIGS. 11 A-l IF).
  • FIGS. 11G-11I a series of bright-field and reflectance images of the labeled SiHa cells obtained with 20X objective using a combination of a white light and a laser-pointer illumination are shown: FIG. 11G white light illumination; FIG. 11H white light with a laser-pointer illumination at grazing incidence; FIG. I ll laser- pointer illumination at grazing incidence.
  • the scattering of gold conjugates is false- colored in red.
  • the laser pointer emits light in 630-680 nm region with power output less than 5 mW.
  • the laser pointer illuminated an area ca. 3-5 mm in diameter.
  • the scale bar is ca. 30 ⁇ m.
  • FIG. 12 is a diagrammatic representation of FIG. 12
  • FIG. 12A, 12C, and 12E Laser scanning confocal reflectance (FIGS. 12A, 12C, and 12E) and confocal fluorescence (FIGS. 12B and 12D) images of pre-cancerous (FIGS. 12A and 12B) and normal (FIGS. 12C, 12D, and 12E) fresh cervical ex vivo tissue labeled with anti- EGFR/gold conjugates are shown.
  • Reflectance images were obtained with 647 nm excitation wavelength and fluorescence images using 488 nm excitation and 515 nm long band-pass emission filter.
  • Reflectance images FIG. 12A and 12C were obtained after labeling with gold conjugates under the same acquisition conditions.
  • FIGS. 12B and 12D were obtained under the same acquisition conditions. The reflectance images are false-colored in red.
  • the scale bar is ca. 20 ⁇ m.
  • FIG. 13 is a diagrammatic representation of FIG. 13
  • Transmittance (FIGS. 13A, 13C, and 13E) and reflectance (FIGS. 13B and 13D) images of engineered tissue constructs labeled with anti-EGFR/gold conjugates are shown.
  • the tissue constructs consist of densely packed, multiple layers of cervical cancer (SiHa) cells.
  • the contrast agents were added on top of the tissue phantoms in 10% polyvinyl pyrrolidone (PNP) solution in PBS (FIGS. 13A and 13B) or in pure PBS (FIGS. 13C and 13D). After incubation for ca.
  • PNP polyvinyl pyrrolidone
  • phantoms were transversely sectioned with a Krumdieck tissue sheer and the sections were imaged using the Zeiss Leica inverted laser scanning confocal microscope with 10X (FIGS. 13A-13D) objective.
  • a small spot on a tissue construct was imaged using 40X oil immersion objective to show high density of the epithelial cells in the phantom (FIG. 13E).
  • Reflectance images were obtained with 647 nm excitation. Arrows show the surfaces exposed to the contrast agents.
  • the scale bars are ca. 200 ⁇ m (FIGS. 13A-13D) and ca. 20 ⁇ m (FIG. 13E).
  • the scattering cross section of gold nanoparticles is extremely high compared to polymeric spheres of the same size (FIG. 10), especially in the red region of the spectrum. This property is important for development of contrast agents for optical imaging in living organisms because light penetration depth in tissue dramatically increases with increasing wavelength.
  • Another interesting optical property of gold nanoparticles that can be exploited for vital optical imaging is the increase in scattering cross section per particle when the particles agglutinate (FIG. 10C). These changes produce a large optical contrast between isolated gold particles and assemblies of gold particles. This increase in contrast improves the ability to image markers which are not uniquely expressed in diseased tissue, but are expressed at higher levels relative to normal tissue (such as EGFR), and to develop highly sensitive labeling procedures which do not require intermediate washing steps to remove single unbound particles.
  • the preparation of gold bioconjugates may be based on non-covalent binding of the anti-EGFR IgG antibodies at their isoelectric point (point of zero net charge of the protein) to gold particles.
  • the complex formation is irreversible and very stable.
  • the anti-EGFR/gold complexes also undergo molecular specific agglutination when anti-IgG polyclonal antibodies are added to the suspension of the conjugates.
  • the agglutination results in increased scattering by the conjugates (FIG. 10C).
  • FIGS. 11A-D show confocal reflectance images and combined transmittance/reflectance images of SiHa cells labeled with anti-EGFR/gold conjugates.
  • the bound conjugates In a series of through focus confocal reflectance images of labeled cells, the bound conjugates first appear as randomly distributed bright spots at the top of the cells, then bright rings can be seen in the optical cross-sections through the middle of the cells.
  • Comparison of the labeling pattern with transmittance images of the cells indicates that labeling predominately occurs on the surface of the cellular cytoplasmic membrane.
  • the labeling pattern is consistent with the fact that the monoclonal antibodies have molecular specificity to the extracellular domain of EGFR.
  • the intensity of light scattering from the labeled SiHa cells is ca. 50 times higher than from unlabeled cells. Therefore unlabeled cells cannot be resolved on the dark background. No labeling was observed when gold conjugates with bovine serum albumin (BSA) were added to the cells (FIGS. 1
  • FIGS. 11G-11I show a series of images of labeled SiHa cells placed on a microscope slide obtained using a 20X objective.
  • the cells with bound gold conjugates appear darker due to light absorption by the metal nanoparticles in the green optical region and the unlabeled cells appear more transparent (FIG. 11 G).
  • the labeled cells appear bright due to scattered light (FIG. 11H).
  • FIG. 1 II shows only labeled cells. No scattering was observed when cells labeled using gold conjugates with BSA were illuminated by a laser pointer under the same conditions.
  • FIG. 12 A Bright "honey-comb” like structures can be seen in laser scanning confocal reflectance images of abnormal cervical biopsies labeled with anti-EGFR/gold complexes. Scattering from the labeled cytoplasmic membranes of epithelial cells forms this pattern. No labeling of the normal biopsy can be seen when the sample is imaged under the same acquisition conditions as the abnormal sample (FIG. 12C). The morphology of the normal biopsy can be resolved after addition of a non-specific contrast agent - acetic acid - and increasing the laser power by ca. 6 fold (FIG. 12E). Acetic acid enhances fluctuations in the nuclear refractive index related to chromatin texture enhancing scattering from nuclei. An increase in scattering of stroma is also evident (FIG. 12E). There is no binding of anti-EGFR/gold conjugates to the stromal layer of cervical biopsies.
  • the epithelial cells exhibit cytoplasmic fluorescence (FIGS. 12B and 12D) due to mitochondrial flavin adenine dinucleotide (FAD).
  • FAD mitochondrial flavin adenine dinucleotide
  • the epithelial cells appear to be su ⁇ ounded by black contours (FIG. 12B). These contours are formed by the bound gold conjugates which strongly absorb visible light in the green optical region where most of the autofluorescence signal is emitted (FIGS. 10B and IOC).
  • the comparison of the reflectance and the fluorescence confocal images of the abnormal biopsy confirms predominant binding of the anti-EGFR/gold conjugates to the cytoplasmic membrane of the epithelial cells (FIGS. 12A and 12B).
  • the contrast agents presented here may yield both anatomic and molecular images of epithelial pathology.
  • a particularly important application is the early detection of precancerous lesions. Early detection of curable precancers may dramatically reduce the incidence and mortality of cancer.
  • In vivo application of these contrast agents requires the ability to deliver the agents throughout the epithelium in the organ site of interest. Pre-cancers of squamous epithelium originate at the basal layer, which can be located 300-500 ⁇ m beneath the tissue surface; therefore, to use diagnostic tools and to study the earliest molecular changes associated with cancer progression it is important to deliver the gold nanoparticles throughout the whole epithelium.
  • penetration enhancers used for topical drug delivery such as polyvinyl py ⁇ olidone (PVP) may be used to deliver the gold nanoparticles throughout the epithelium (FIG. 13).
  • PVP polyvinyl py ⁇ olidone
  • the anti-EGFR/gold conjugates were applied to the top of engineered tissue constructs in pure PBS buffer and in PBS in the presence of 10% PVP. After ca. 30 minutes incubation, constructs were washed in PBS and 200 ⁇ m thick transverse sections were prepared and imaged using transmittance and confocal reflectance microscopies (FIG. 13).
  • contrast agents presented here indicate the ability to extend vital reflectance microscopies for in vivo molecular imaging. Using these contrast agents, we demonstrated the ability to image the distribution of EGFR expression in living neoplastic cervical tissue - providing the ability to assess molecular pathology in vivo.
  • OCM and RCM yield images of tissue microanatomy similar to that which can be obtained with conventional histopathology; contrast agents based on gold nanoparticles provide a strong source of signal with molecular specificity that is immune to photobleaching.
  • DOT Diffuse optical tomography
  • contrast agents based on gold nanoparticles make them ideally suited for vital imaging and in vivo diagnosis.
  • surface plasmon resonances can be selected to take advantage of regions where tissue is most transparent depending on the degree of tissue penetration required.
  • multi-color labeling for many targets can be achieved.
  • the enhanced scattering from closely spaced gold particles confers important advantages for in vivo imaging. First, the scattering from aggregates of bound particles is greatly enhanced compared to background scattering from unbound particles. Additionally, many markers are not uniquely expressed in disease,, but are over- or under-expressed. The scattering from closely spaced aggregates associated with over-expression can magnify the signal difference owing to moderate levels of over-expression.
  • Contrast agents based on gold nanoparticle antibody conjugates may be put to in vivo use, with topical or systemic delivery.
  • the inherent biocompatibility of gold means that they can be used directly in vivo without the need for protective layer growth.
  • long term treatment of rheumatoid arthritis utilizes gold (up to a cumulative dose of 1.2-1.8 g/year for up to 10 years).
  • We anticipate that less than 0.3 mg of gold may be required for diagnosis with topical delivery to the cervix.
  • Humanized antibodies, where a mouse antibody-binding site is transfe ⁇ ed to a human antibody gene are much less immunogenic in humans, and many humanized antibodies are currently in clinical trials.
  • the FDA has approved more than 10 monoclonal antibody based drugs, including Herceptin for metastatic breast cancer therapy.
  • Herceptin for metastatic breast cancer therapy.
  • simple FDA approved agents such as polyvinylpy ⁇ olidone can be used to increase tissue permeability and deliver contrast agents topically.
  • MMPs metallo-proteases
  • MMP-9 monoclonal antibodies for MMP-2 (data not shown) and MMP-9.
  • the conjugates were used to label cervical epithelial cancer cells grown on two different substrates: a pure collagen I gel and a collagen I gel in the presence of 5% gelatin.
  • SiHa cells were placed on a substrate and allowed to grow for 5-24 hrs in DMEM with 5% FBS at 37°C and 5% CO 2 , and then antibody-gold conjugates were applied to a sample in PBS for 20-30 minutes under sterile conditions.
  • FIG. 14 shows the results of labeling of SiHa cells grown on collagen I substrate with anti-MMP-9/gold conjugates. Significant labeling of cellular cytoplasm was observed. Cytoplasmic labeling may be associated with internalization of labeled MMP-9 molecules from the plasma membrane. Rapid internalization and degradation of MMPs including MMP-9 is an important mechanism in regulating extracellular proteinase activity. We also observed strong labeling of collagen fibers located along clusters of cells (FIG. 14A and 14C).
  • Contrast agents may be utilized to image molecular features of human papillomavirus (HPV) induced cervical carcinogenesis. Persistence and progression of cervical cancer is clearly related to expression of the viral oncoproteins, E6 and E7.
  • FIG. 15 shows preliminary results obtained labeling SiHa cells with 10 nm gold nanoparticles conjugated to anti-E7 monoclonal antibodies.
  • Cells were incubated in contrast agent in PBS and in PBS with 10% PVP. Following incubation, cells were washed and imaged using laser scanning confocal microscopy.
  • FIG. 15 shows the co-localized autofluorescence (green) and reflectance (white) images from SiHa cells incubated with PVP. Autofluorescence is limited to the cytoplasm, whereas backscattering is produced by nanoparticles within the nucleus. No backscattering was observed in cells incubated with contrast agent in PBS alone. Thus, delivery and detection of contrast agent is feasible. In data, we observed at least a three fold, statistically significant increase in nuclear backscattering from nanoparticles in cells with high E7 expression compared to cells with low E7 expression.
  • Contrast agents based on gold nanoparticle antibody conjugates may be used in vivo, with topical or systemic delivery.
  • the inherent biocompatibility of gold implies they can be used directly in vivo without the need for protective layer growth.
  • long term treatment of rheumatoid arthritis utilizes gold (up to a cumulative dose of 1.2-1.8 g/year for up to 10 years).
  • We anticipate that less than 0.3 mg of gold may be required for diagnosis with topical delivery to the cervix.
  • Humanized antibodies, where a mouse antibody-binding site is transfe ⁇ ed to a human antibody gene are much less immunogenic in humans, and many humanized antibodies are currently in clinical trials.
  • the FDA has approved more than 10 monoclonal antibody based drugs, including Herceptin for metastatic breast cancer therapy.
  • Herceptin for metastatic breast cancer therapy.
  • simple FDA approved agents such as polyvinylpyrrolidone can be used to increase tissue permeability and deliver contrast agents topically.
  • Optically active contrast agents to target the molecular signatures of neoplasia.
  • Metal NPs Optically active contrast agents to target the molecular signatures of neoplasia.
  • Vital reflectance imaging using both gold and silver nanoparticles may be accomplished using the techniques of this invention. Contrast agents based on gold nanoparticles may be used because gold is biocompatible and can be used directly for in vivo applications. Silver particles may be used also. Silver may exhibit higher extinction coefficients and provide higher enhancements of the local electromagnetic field and exhibit other effects associated with optical excitation of surface plasmon resonances. Silver particles are not as stable and not as biocompatible as gold nanoparticles. This issue can be addressed by encapsulating silver particles inside an inert material. One may use a silica coating developed by Dr. Sokolov in Sokolov, K., G. Chumanov, and T.M. Cotton, Enhancement of Molecular Fluorescence near the
  • Gold and silver colloidal particles can be prepared from chloroauric acid
  • HAV 4 silver nitrate
  • AgNO silver nitrate
  • reducing agents including phosphorous, ascorbic acid, sodium citrate, borohydrate.
  • sodium citrate may be used.
  • Highly uniform gold colloids with particle sizes ranging from about 10 nm to ca. 100 nm can be prepared using sodium citrate reduction of chloroauric acid. This colloid exhibits a single extinction peak ranging from 500 nm to about 540 nm depending on the size of the particles.
  • Sodium citrate reduction of silver nitrate results in a colloidal solution with about 35 nm diameter silver particles and a single peak at approximately 410 nm.
  • silver particles with narrower distributions and different mean diameters can be prepared using a starter hydrosol with small gold or silver particles that provides nucleation centers for growth of bigger silver colloid.
  • the materials include a dielectric optically inert core particle and an optically active gold shell and can be prepared in a variety of sizes and in a highly uniform fashion.
  • Another approach to tune optical properties of metal nanoparticles is based on template synthesis such as that in Haes, A.J. and R.P. Van Duyne, A nanoscale optical biosensor: Sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. Journal of the American Chemical Society, 2002. 124(35): p. 10596-10604, which is incorporated by reference.
  • metal nanoparticles of pyramidal shape with different sizes can be synthesized inside cavities formed by a dense monolayer of polystyrene beads on a flat substrate. After synthesis the nanoparticles can be removed from the surface by a simple one step procedure. These approaches may be used to optimize scattering properties of nanoparticles to take advantage of optical regions where tissue is most transparent depending on the degree of tissue penetration required.
  • Another venue may be to use particles of different sizes conjugated to different probe molecules to achieve multi-color labeling for many targets.
  • FIG. 8 summarizes embodiments for preparation of conjugates of gold particles with cancer specific probe molecules.
  • probe molecules may be used: well established commercially available antibodies for molecular biomarkers of cancer and peptides specifically developed to bind to cancer biomarkers.
  • One may utilize humanized antibodies.
  • a second conjugation strategy for antibodies may include preparation of biotinylated antibody molecules and their consequent interaction with streptavidin/gold conjugates (FIG. 8).
  • This approach takes advantage of strong biospecific interaction between biotin and streptavidin and a well-developed protocol for immobilization of streptavidin on gold particles. Smaller peptide molecules can not be directly adsorbed on the gold surface because that could significantly change their conformation and lead to loss of binding properties.
  • Peptides with thiol terminated alkyl chains may be directly attached to the surface of gold particles similar to the procedures described in Elghanian, R., et al., Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles. Science, 1997.
  • the immobilization of antibodies and thiol terminated peptides on silver particles may be accomplished using strategies similar to those utilized for gold particles.
  • Silver conjugates may not have the same stability and shelf life as the gold conjugates, however they can be used to evaluate the silver based contrast agents.
  • Conjugation protocols for silica capped silver particles may be formed (FIG. 8).
  • the silica layer may be formed using tetraethyl orthosilicate (TEOS).
  • TEOS tetraethyl orthosilicate
  • Many silanization reagents are available to introduce functional groups to silica surfaces for subsequent protein immobilization.
  • thiol terminated peptide molecules To co-adsorb thiol terminated peptide molecules and thiol-PEG, one may mix the two compounds together and apply them to gold nanoparticles at the same time. In this case the reaction can be simply controlled by adjusting relative amount of peptides and PEG molecules.
  • Boone CW Bacus JW, Bacus JV, Steele VE, Kelloff GJ. Properties of intraepithehal neoplasia relevant to cancer chemoprevention and to the development of su ⁇ ogate end points for clinical trials (44165). Proc Soc Exp Biol Med 1997;216:151-65.
  • Nanocrystals as Fluorescent Biological Labels Science 1998, 281, 2013.
  • Adachi, M., et al. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer.
  • Clinical cancer research an official journal of the American Association for Cancer Research, 2000. 6(1): p. 96-101. 226.
  • Chatterjee, N. and A. Chatterjee Role of alphavbeta3 integrin receptor in the invasive potential of human cervical cancer (SiHa) cells. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2001. 20(3): p. 211-21. 227.
  • Hamidi, S., et al. Expression of alpha(v)beta6 integrin in oral leukoplakia.
  • Collier, T., et al. Near Real-Time Confocal Microscopy of Amelanotic Tissue: Detection of Dysplasia in ex Vivo Cervical Tissue. Academic Radiology, 2002. 9(5): p. 504-512. 244.
  • Collier, T., et al. Near Real Time Confocal Microscopy of Amelanotic Tissue: Dynamics of Aceto-Whitening Enable Nuclear Segmentation. Optics Express, 2000. 6(2): p. 40-48.
  • Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 2000. 60(3): p.
  • Berkower I Affiliation Laboratory of Immunoregulation, D.o.A.P., O.oN.R.C.f.B.F. Parasitology, and B.M.D.U.S.A.B.ax.f.g. Drug Administration, The promise and pitfalls of monoclonal antibody therapeutics.
  • TMC N-trimethylated chitosan chloride
  • MMP-1 and -2 matrix metalloproteinases
  • TMP-1, -2 and -3 inhibitors
  • Ke, L.D., et al. Expression of human papiUomavirus E7 mRNA in human oral and cervical neoplasia and cell lines. 464. Ke, L.D., et al., Differential expression of epidermal growth factor receptor in human head and neck cancers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

L'invention concerne des méthodes et des dispositifs servant à détecter un état d'un échantillon (y compris des cancers et des pré-cancers du col de l'utérus) par imagerie par réflexion et/ou par fluorescence. Les méthodes de l'invention consistent à utiliser un échantillon et une ou plusieurs nanoparticules métalliques et/ou un ou plusieurs points quantiques (A), à relier les nanoparticules métalliques et/ou les points quantiques à un ou plusieurs biomarqueurs (B) de l'échantillon associés à l'état, et à prendre une image (C) par réflexion et/ou par fluorescence de l'échantillon. La ou les images présentent une diffusion optique caractéristique aux nanoparticules et/ou une excitation de fluorescence caractéristique aux points quantiques, indiquant la présence des biomarqueurs. Ainsi, l'état peut être facilement dépisté ou diagnostiqué.
PCT/US2003/006730 2002-03-05 2003-03-05 Produits de contraste biospecifiques WO2003075765A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03711417A EP1487343B1 (fr) 2002-03-05 2003-03-05 Produits de contraste biospecifiques
AU2003213729A AU2003213729A1 (en) 2002-03-05 2003-03-05 Biospecific contrast agents
DE60325564T DE60325564D1 (de) 2002-03-05 2003-03-05 Biospezifische kontrastmittel
CA002478083A CA2478083A1 (fr) 2002-03-05 2003-03-05 Produits de contraste biospecifiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36192402P 2002-03-05 2002-03-05
US60/361.924 2002-03-05

Publications (1)

Publication Number Publication Date
WO2003075765A1 true WO2003075765A1 (fr) 2003-09-18

Family

ID=27805093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006730 WO2003075765A1 (fr) 2002-03-05 2003-03-05 Produits de contraste biospecifiques

Country Status (7)

Country Link
US (2) US20040023415A1 (fr)
EP (1) EP1487343B1 (fr)
AT (1) ATE419536T1 (fr)
AU (1) AU2003213729A1 (fr)
CA (1) CA2478083A1 (fr)
DE (1) DE60325564D1 (fr)
WO (1) WO2003075765A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574859A1 (fr) * 2004-03-10 2005-09-14 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Procédé de caractérisation de surfaces artificielles
WO2005113817A3 (fr) * 2004-05-03 2006-05-26 Nanosphere Inc Conjugues nanoparticules-aptameres, et leur procede d'utilisation pour detecter un analyte cible
WO2006131853A2 (fr) 2005-06-07 2006-12-14 Koninklijke Philips Electronics N.V. Profilage d'une expression in vivo
EP2060916A1 (fr) * 2006-09-14 2009-05-20 Konica Minolta Medical & Graphic, Inc. Ensemble microparticules semi-conductrices fluorescentes, ensemble agent de marquage fluorescent pour substances biologiques, et procédé de bio-imagerie et procédé d'analyse de substances biologiques au moyen de ces ensembles
EP2185175A2 (fr) * 2007-08-15 2010-05-19 Yeda Research And Development Co. Ltd. Régulateurs de la mmp-9 et leurs utilisations

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8614169B2 (en) * 2001-12-04 2013-12-24 Wayne State University Neoepitope detection of disease using protein arrays
US7964536B2 (en) * 2001-12-04 2011-06-21 Wayne State University Neoepitope detection of disease using protein arrays
WO2003075765A1 (fr) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Produits de contraste biospecifiques
JP2006508095A (ja) 2002-05-07 2006-03-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 粒子の生物活性化
US7810380B2 (en) 2003-03-25 2010-10-12 Tearlab Research, Inc. Systems and methods for collecting tear film and measuring tear film osmolarity
US8020433B2 (en) * 2003-03-25 2011-09-20 Tearlab Research, Inc. Systems and methods for a sample fluid collection device
US6965434B2 (en) * 2002-09-13 2005-11-15 Centre National De La Recherche Scientifiques (C.N.R.S.) Method and device for photothermal imaging tiny metal particles immersed in a given medium
US7623908B2 (en) * 2003-01-24 2009-11-24 The Board Of Trustees Of The University Of Illinois Nonlinear interferometric vibrational imaging
JP4787938B2 (ja) * 2003-03-28 2011-10-05 ザ・プロウボウスト・フェロウズ・ファウンデーション・スカラーズ・アンド・ザ・アザー・メンバーズ・オブ・ボード・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン 銀ナノ粒子を用いた検体検出用センサ
JP2007516843A (ja) * 2003-10-20 2007-06-28 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 分子相互作用を検出するためのナノスケール変換システム
AU2003285133A1 (en) * 2003-11-05 2005-06-24 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Biofunctionalized quantum dots for biological imaging
US7610074B2 (en) * 2004-01-08 2009-10-27 The Board Of Trustees Of The University Of Illinois Multi-functional plasmon-resonant contrast agents for optical coherence tomography
US20050220714A1 (en) * 2004-04-01 2005-10-06 Susan Kauzlarich Agents for use in magnetic resonance and optical imaging
WO2005107818A2 (fr) * 2004-04-30 2005-11-17 University Of Florida Nanoparticules et leur utilisation dans la bioimagerie multifonctions
US7943396B2 (en) * 2004-06-22 2011-05-17 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
US7655479B2 (en) * 2004-06-30 2010-02-02 University Of South Florida Luminescence characterization of quantum dots conjugated with biomarkers for early cancer detection
US20060057627A1 (en) * 2004-09-08 2006-03-16 Board Of Regents, The University Of Texas System Selection scheme for enzymatic function
CA2520670A1 (fr) * 2004-09-23 2006-03-23 National Research Council Of Canada Surfaces enduites de nanocristaux
US20080093550A1 (en) * 2004-11-12 2008-04-24 Seoul National University Industry Foundation Method For Adhering Nanostructures to End of Probe of Microscope and Microscope Having Probe Made By the Same Method
US8346346B1 (en) 2005-01-24 2013-01-01 The Board Of Trustees Of The Leland Stanford Junior University Optical analysis system and approach therefor
US8788021B1 (en) 2005-01-24 2014-07-22 The Board Of Trustees Of The Leland Stanford Junior Univerity Live being optical analysis system and approach
US7307774B1 (en) 2005-01-24 2007-12-11 The Board Of Trustees Of The Leland Standford Junior University Micro-optical analysis system and approach therefor
US7586618B2 (en) 2005-02-28 2009-09-08 The Board Of Trustees Of The University Of Illinois Distinguishing non-resonant four-wave-mixing noise in coherent stokes and anti-stokes Raman scattering
US7725169B2 (en) * 2005-04-15 2010-05-25 The Board Of Trustees Of The University Of Illinois Contrast enhanced spectroscopic optical coherence tomography
US8454511B2 (en) 2005-05-27 2013-06-04 Board Of Regents, The University Of Texas System Magneto-motive ultrasound detection of magnetic nanoparticles
US8355776B2 (en) 2005-05-27 2013-01-15 Board Of Regents, The University Of Texas System Hemoglobin contrast in magneto-motive optical doppler tomography, optical coherence tomography, and ultrasound imaging methods and apparatus
WO2006128167A2 (fr) * 2005-05-27 2006-11-30 Board Of Regents, The University Of Texas System Detection de cellules et de compositions par tomographie par coherence optique
US7801590B2 (en) * 2005-05-27 2010-09-21 Board Of Regents, The University Of Texas System Optical coherence tomographic detection of cells and killing of the same
US7499161B2 (en) * 2005-07-05 2009-03-03 The Board Of Regents Of The University Of Texas System Depth-resolved spectroscopy method and apparatus
JP2007023058A (ja) * 2005-07-12 2007-02-01 Fujifilm Holdings Corp 金属酸化物又は金属硫化物ナノ粒子蛍光体を用いる癌検出方法
WO2007090147A2 (fr) 2006-01-31 2007-08-09 The Board Of Trustees Of The University Of Illinois Procédé et appareil de mesure des propriétés optiques de tissus
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US8026108B1 (en) * 2006-10-19 2011-09-27 The University Of Central Florida Research Foundation, Inc. Detection of biotargets using bioreceptor functionalized nanoparticles
US7654716B1 (en) 2006-11-10 2010-02-02 Doheny Eye Institute Enhanced visualization illumination system
US9476830B2 (en) 2006-11-21 2016-10-25 California Institute Of Technology Second harmonic imaging nanoprobes and techniques for use thereof
US8426152B2 (en) * 2007-01-03 2013-04-23 Lamdagen Corporation Enzymatic assay for LSPR
GB0701444D0 (en) * 2007-01-25 2007-03-07 Iti Scotland Ltd Detecting analytes
WO2008101019A2 (fr) * 2007-02-13 2008-08-21 Board Of Regents, The University Of Texas System Imagerie photo-acoustique spécifique moléculaire
WO2008106590A2 (fr) * 2007-02-28 2008-09-04 Doheny Eye Institute Système d'éclairage portatif pouvant être tenu à la main
AU2008232439B2 (en) * 2007-04-02 2014-10-09 Emory University In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
AU2008296733B2 (en) 2007-08-08 2013-07-11 The Board Of Regents Of The University Of Texas System VEGFR-1/NRP-1 targeting peptides
US8238942B2 (en) * 2007-11-21 2012-08-07 Trapeze Networks, Inc. Wireless station location detection
US8115934B2 (en) 2008-01-18 2012-02-14 The Board Of Trustees Of The University Of Illinois Device and method for imaging the ear using optical coherence tomography
US8983580B2 (en) 2008-01-18 2015-03-17 The Board Of Trustees Of The University Of Illinois Low-coherence interferometry and optical coherence tomography for image-guided surgical treatment of solid tumors
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
US8488863B2 (en) * 2008-11-06 2013-07-16 Los Alamos National Security, Llc Combinational pixel-by-pixel and object-level classifying, segmenting, and agglomerating in performing quantitative image analysis that distinguishes between healthy non-cancerous and cancerous cell nuclei and delineates nuclear, cytoplasm, and stromal material objects from stained biological tissue materials
US8945471B2 (en) * 2009-01-21 2015-02-03 California Institute Of Technology Multipurpose analysis using second harmonic generating nanoprobes
US20100234762A1 (en) * 2009-02-27 2010-09-16 Gary Pond Compositions and methods for detecting oral neoplasm
WO2011041701A2 (fr) * 2009-10-02 2011-04-07 The Brigham And Women's Hospital, Inc. Agents de contraste implantables et procédés
EP3372206A1 (fr) 2010-05-13 2018-09-12 Doheny Eye Institute Systèmes et dispositifs de canule de perfusion éclairée autonome
US9448173B2 (en) 2011-03-08 2016-09-20 The Board Of Trustees Of The University Of Illinois Dye-conjugated dendrimers
US9417240B2 (en) 2011-05-27 2016-08-16 Drexel University Capped and conjugated quantum dots
US9155497B1 (en) 2011-06-02 2015-10-13 Stc.Unm Compact biosensor of matrix metalloproteinase with cadmium free quantum dots
WO2013063588A1 (fr) * 2011-10-28 2013-05-02 The Board Of Trustees Of The Leland Stanford Junior University Culture ex vivo, prolifération et expansion d'organoïdes tissulaires primaires
WO2013078410A1 (fr) 2011-11-21 2013-05-30 California Institute Of Technology Fonctionnalisation et utilisation de nano-sondes fonctionnalisées à génération de second harmonique
US8984733B2 (en) 2013-02-05 2015-03-24 Artventive Medical Group, Inc. Bodily lumen occlusion
ES2709886T3 (es) * 2013-02-20 2019-04-22 Univ Cornell Nanopartículas fluorescentes multicapa y procedimientos de fabricación y uso de las mismas
US9636116B2 (en) 2013-06-14 2017-05-02 Artventive Medical Group, Inc. Implantable luminal devices
US10149968B2 (en) * 2013-06-14 2018-12-11 Artventive Medical Group, Inc. Catheter-assisted tumor treatment
US9092691B1 (en) * 2014-07-18 2015-07-28 Median Technologies System for computing quantitative biomarkers of texture features in tomographic images
US11536707B2 (en) 2014-09-23 2022-12-27 Tearlab Research, Inc. Systems and methods for integration of microfluidic tear collection and lateral flow analysis of analytes of interest
WO2016049544A1 (fr) 2014-09-25 2016-03-31 Northwestern University Dispositifs, procédés et systèmes se rapportant à l'imagerie très haute définition
US10588564B2 (en) * 2014-09-30 2020-03-17 Moein Health, LLC Method and kit for diagnosing and treating neoplastic tissue
US20160178519A1 (en) * 2014-12-23 2016-06-23 Boston Scientific Scimed, Inc. Marker For Detection And Confirmation Of Peripheral Lung Nodules
TWI608076B (zh) * 2015-03-04 2017-12-11 納諾柯技術有限公司 以金屬硫醇聚合物穩定化的量子點
MX393857B (es) 2015-07-22 2025-03-24 Univ Autonoma De San Luis Potosi Detección cuantitativa del ácido siálico utilizando el efecto raman realzado por superficies.
US10813644B2 (en) 2016-04-01 2020-10-27 Artventive Medical Group, Inc. Occlusive implant and delivery system
US11180735B2 (en) 2016-10-28 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof
US10634890B1 (en) 2018-10-26 2020-04-28 General Electric Company Miniaturized microscope for phase contrast and multicolor fluorescence imaging
US20220082500A1 (en) * 2019-01-17 2022-03-17 University Health Network Tissue phantoms
WO2021113450A2 (fr) * 2019-12-05 2021-06-10 Imaginab, Inc. Procédés d'imagerie utilisant de multiples agents d'imagerie
CN118900702A (zh) * 2022-01-19 2024-11-05 黄雀诊断公司 含有金属纳米颗粒的组合物及其制备方法与用途

Citations (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203089A1 (fr) 1984-10-19 1986-12-03 Technology Licence Company Limited Anticorps monoclonaux et leur utilisation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
WO1991019813A1 (fr) 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Ligands d'acide nucleique
WO1992005285A1 (fr) 1990-09-21 1992-04-02 Fred Hutchinson Cancer Research Center Sequences d'oligonucleotides specifiques de sequences de proteines
WO1992014843A1 (fr) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamere specifique de biomolecules et procede de production
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5562100A (en) 1988-12-21 1996-10-08 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5612540A (en) 1995-03-31 1997-03-18 Board Of Regents, The University Of Texas Systems Optical method for the detection of cervical neoplasias using fluorescence spectroscopy
US5623932A (en) 1993-05-12 1997-04-29 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluorescence
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5697373A (en) 1995-03-14 1997-12-16 Board Of Regents, The University Of Texas System Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies
US5699795A (en) 1995-03-31 1997-12-23 Board Of Regents, The University Of Texas System Optical probe for the detection of cervical neoplasia using fluorescence spectroscopy and apparatus incorporating same
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5780449A (en) 1995-11-24 1998-07-14 Crinos Industria Farmacobiologica S.P.A. Cathepsin G-inhibiting aptamers
US5780610A (en) 1994-08-30 1998-07-14 Collins; Mark L. Reduction of nonspecific hybridization by using novel base-pairing schemes
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
US5842995A (en) 1996-06-28 1998-12-01 Board Of Regents, The Univerisity Of Texas System Spectroscopic probe for in vivo measurement of raman signals
US5861501A (en) 1995-06-07 1999-01-19 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5920399A (en) 1997-03-18 1999-07-06 Sandia Corporation Multispectral imaging method and apparatus
US5929985A (en) 1997-03-18 1999-07-27 Sandia Corporation Multispectral imaging probe
US5991653A (en) 1995-03-14 1999-11-23 Board Of Regents, The University Of Texas System Near-infrared raman spectroscopy for in vitro and in vivo detection of cervical precancers
US6135965A (en) 1996-12-02 2000-10-24 Board Of Regents, The University Of Texas System Spectroscopic detection of cervical pre-cancer using radial basis function networks
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6187289B1 (en) 1997-10-20 2001-02-13 Board Of Regents, The University Of Texas System Acetic acid as a contrast in reflectance confocal imaging of tissue
US6251616B1 (en) * 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response
US6258576B1 (en) 1996-06-19 2001-07-10 Board Of Regents, The University Of Texas System Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy
US6275726B1 (en) 1997-05-15 2001-08-14 Board Of Regents, The University Of Texas System Methods of enhanced light transmission through turbid biological media
US6287768B1 (en) * 1998-01-07 2001-09-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8331514D0 (en) * 1983-11-25 1984-01-04 Janssen Pharmaceutica Nv Visualization method
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US5217594A (en) * 1992-01-15 1993-06-08 Enzyme Technology Research Group, Inc. Convenient determination of trace lead in whole blood and other fluids
AU2121497A (en) * 1996-02-22 1997-09-10 Dexall Biomedical Labs, Inc. Non-captive substrate liquid phase immunoassay
US5750411A (en) * 1996-06-03 1998-05-12 Bayer Corporation Sol particle decay protection immunoassay
US5939021A (en) * 1997-01-23 1999-08-17 Hansen; W. Peter Homogeneous binding assay
US6699724B1 (en) * 1998-03-11 2004-03-02 Wm. Marsh Rice University Metal nanoshells for biosensing applications
WO2000026671A1 (fr) * 1998-10-29 2000-05-11 Connex Gmbh Determination de la presence de micro-organismes resistant aux acides dans des selles
US6465180B1 (en) * 1999-03-17 2002-10-15 The Regents Of The University Of California Detection of premalignant melanocytes
US20010055764A1 (en) * 1999-05-07 2001-12-27 Empedocles Stephen A. Microarray methods utilizing semiconductor nanocrystals
US6680377B1 (en) * 1999-05-14 2004-01-20 Brandeis University Nucleic acid-based detection
CA2387503C (fr) * 1999-10-26 2010-02-09 University Of Utah Research Foundation Cobalamines fluorescentes et utilisations
WO2003075765A1 (fr) * 2002-03-05 2003-09-18 Board Of Regents, The University Of Texas System Produits de contraste biospecifiques

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0203089A1 (fr) 1984-10-19 1986-12-03 Technology Licence Company Limited Anticorps monoclonaux et leur utilisation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5562100A (en) 1988-12-21 1996-10-08 Massachusetts Institute Of Technology Method for laser induced fluorescence of tissue
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
WO1991019813A1 (fr) 1990-06-11 1991-12-26 The University Of Colorado Foundation, Inc. Ligands d'acide nucleique
WO1992005285A1 (fr) 1990-09-21 1992-04-02 Fred Hutchinson Cancer Research Center Sequences d'oligonucleotides specifiques de sequences de proteines
WO1992014843A1 (fr) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamere specifique de biomolecules et procede de production
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US5623932A (en) 1993-05-12 1997-04-29 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluorescence
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US5780610A (en) 1994-08-30 1998-07-14 Collins; Mark L. Reduction of nonspecific hybridization by using novel base-pairing schemes
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5697373A (en) 1995-03-14 1997-12-16 Board Of Regents, The University Of Texas System Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies
US5991653A (en) 1995-03-14 1999-11-23 Board Of Regents, The University Of Texas System Near-infrared raman spectroscopy for in vitro and in vivo detection of cervical precancers
US6095982A (en) 1995-03-14 2000-08-01 Board Of Regents, The University Of Texas System Spectroscopic method and apparatus for optically detecting abnormal mammalian epithelial tissue
US5699795A (en) 1995-03-31 1997-12-23 Board Of Regents, The University Of Texas System Optical probe for the detection of cervical neoplasia using fluorescence spectroscopy and apparatus incorporating same
US5612540A (en) 1995-03-31 1997-03-18 Board Of Regents, The University Of Texas Systems Optical method for the detection of cervical neoplasias using fluorescence spectroscopy
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5861501A (en) 1995-06-07 1999-01-19 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US5780449A (en) 1995-11-24 1998-07-14 Crinos Industria Farmacobiologica S.P.A. Cathepsin G-inhibiting aptamers
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US6258576B1 (en) 1996-06-19 2001-07-10 Board Of Regents, The University Of Texas System Diagnostic method and apparatus for cervical squamous intraepithelial lesions in vitro and in vivo using fluorescence spectroscopy
US5842995A (en) 1996-06-28 1998-12-01 Board Of Regents, The Univerisity Of Texas System Spectroscopic probe for in vivo measurement of raman signals
US6135965A (en) 1996-12-02 2000-10-24 Board Of Regents, The University Of Texas System Spectroscopic detection of cervical pre-cancer using radial basis function networks
US5929985A (en) 1997-03-18 1999-07-27 Sandia Corporation Multispectral imaging probe
US5920399A (en) 1997-03-18 1999-07-06 Sandia Corporation Multispectral imaging method and apparatus
US6275726B1 (en) 1997-05-15 2001-08-14 Board Of Regents, The University Of Texas System Methods of enhanced light transmission through turbid biological media
US6187289B1 (en) 1997-10-20 2001-02-13 Board Of Regents, The University Of Texas System Acetic acid as a contrast in reflectance confocal imaging of tissue
US6241662B1 (en) 1997-10-20 2001-06-05 Lifespex, Inc. Acetic acid as a signal enhancing contrast agent in fluorescence spectroscopy
US6287768B1 (en) * 1998-01-07 2001-09-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US6251616B1 (en) * 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response

Non-Patent Citations (38)

* Cited by examiner, † Cited by third party
Title
"Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY
1988: "Bethesda System for reporting cervical/vaginal cytologic diagnoses. National Cancer Institute Workshop", JAMA, vol. 262, 1989, pages 931 - 934
AVERITT, R.D.; S.L. WESTCOTT; N.J. HALAS: "The Linear Optical Properties of Gold Nanoshells", J. OPT SOC AM B, vol. 16, 1999, pages 1824 - 32, XP007907328, DOI: doi:10.1364/JOSAB.16.001824
B.W. POGUE ET AL.: "Biomedical Optical Spectroscopy and Diagnostics Technical Digest", 1998, OPTICAL SOCIETY OF AMERICA, article "Development of a Spectrally Resolved Colposcope for early detection of Cervical Cancer", pages: 87 - 89
CHAROUS, S.J. ET AL.: "Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma", THE ANNALS OF OTOLOGY, RHINOLOGY, AND LARYNGOLOGY, vol. 106, no. 4, 1997, pages 271 - 8
DALY MB.: "The chemoprevention of cancer: Directions for the future", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 2, 1993, pages 509 - 12
DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014
ELGHANIAN, R. ET AL.: "Selective colorimetric detection of polynucleotides based on the distance-dependent optical properties of gold nanoparticles", SCIENCE, vol. 277, no. 5329, 1997, pages 1078 - 1080, XP002566839, DOI: doi:10.1126/science.277.5329.1078
FRENS, G., NATURE PHYSICAL SCIENCE, vol. 241, 1973, pages 20 - 22
GEOGHEGAN, W.D.; G.A. ACKERMAN, THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY : OFFICIAL JOURNAL OF THE HISTOCHEMISTRY SOCIETY, vol. 25, no. 11, 1977, pages 1187 - 200
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
HAES, A.J.; R.P. VAN DUYNE: "A nanoscale optical biosensor: Sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 35, 2002, pages 10596 - 10604
HOFFMOAN, P. ET AL.: "Adenovirus E3 Protein causes Constitutively Internatized Epidermal Growth Factor Receptor To Accomolate in a Prelysosomal Compartment Resulting in Euhanced Degradation", MOLECULAR AND CELLULAR BIOLOGY, vol. 14, no. 6, 1994, pages 3695 - 3706
HORISBERGER, M.: "Colloidal gold : a cytochemical marker for light and fluorescent microscopy and for transmission and scanning electron microscopy", SCAN ELECTRON MICROSC, vol. 2, 1981, pages 9 - 31, XP009048714
HUNTER ET AL., NATURE, vol. 144, 1962, pages 945
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
JOYCE, GENE, vol. 82, 1989, pages 83 - 87
KE, L.D. ET AL., DIFFERENTIAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR IN HUMAN HEAD AND NECK CANCERS
KE, L.D. ET AL., EXPRESSION OF HUMAN PAPILLOMAVIRUS E7 MRNA IN HUMAN ORAL AND CERVICAL NEOPLASIA AND CELL LINES
KELLOFF GJ ET AL.: "Surrogate endpoint biomarkers for phase II cancer chemoprevention trials", J CELL BIOCHEM SUPPL, vol. 19, 1994, pages 1 - 9, XP009090575, DOI: doi:10.1002/jcb.240560903
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495
KOSS LG.: "The Papanicolaou test for cervical cancer detection. A triumph and a tragedy [see comment citation in Medline", JAMA, vol. 261, 1989, pages 737 - 743
MORRISON ET AL., PROC. NAT. ACAD. SCI., vol. 81, 1984, pages 6851
NYGREN, J. HISTOCHEM. AND CYTOCHEM., vol. 30, 1982, pages 407
PAIN ET AL., J. IMMUNOL. METH., vol. 40, 1981, pages 219
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
S. L. JACQUES; J.R. ROMAN; K. LEE: "Imaging Superficial Tissues with Polarized Light", LASERS SURG. MED., vol. 26, 2000, pages 119 - 129
S. LAM ET AL.: "Detection of Dysplasia and Carcinoma In Situ with a Lung Imaging Fluorescence Endoscope Device", J OF THORACIC & CARDIOVASCULAR SURGERY, vol. 105, no. 6, 1993, pages 1035 - 40
S. LAM ET AL.: "Localization of Bronchial Intraepithelial Neoplastic Lesions by Fluorescence Bronchoscopy", CHEST, vol. 113, no. 2, 1998, pages 696 - 702
SERSHEN, S.R. ET AL.: "Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 51, no. 3, 2000, pages 293 - 8, XP002324001, DOI: doi:10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
SMITHPETER C ET AL.: "Real Time Confocal Microscopy of In Situ Amelanotic Cells: Sources of Signal, Contrast Agents and Limits of Contrast", JOURNAL OF BIOMEDICAL OPTICS, vol. 3, 1998, pages 429 - 36
SOKOLOV, K. ET AL., OPTICS EXPRESS, vol. 5, no. 13, 1999, pages 302 - 317
SOKOLOV, K.; G. CHUMANOV; T.M. COTTON: "Enhancement of Molecular Fluorescence near the Surface of Colloidal Metal Films", ANALYTICAL CHEMISTRY, vol. 70, no. 18, 1998, pages 3898 - 3905, XP002267405, DOI: doi:10.1021/ac9712310
SURESH ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1986, pages 210
SUTINEN, M. ET AL.: "Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis", BRITISH JOURNAL OF CANCER, vol. 77, no. 12, 1998, pages 2239 - 45
SZOSTAK ET AL., NATURE, vol. 346, 1990, pages 818 - 822
TUERK ET AL., SCIENCE, vol. 249, 1990, pages 505 - 510
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574859A1 (fr) * 2004-03-10 2005-09-14 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Procédé de caractérisation de surfaces artificielles
WO2005113817A3 (fr) * 2004-05-03 2006-05-26 Nanosphere Inc Conjugues nanoparticules-aptameres, et leur procede d'utilisation pour detecter un analyte cible
WO2006131853A2 (fr) 2005-06-07 2006-12-14 Koninklijke Philips Electronics N.V. Profilage d'une expression in vivo
WO2006131853A3 (fr) * 2005-06-07 2007-03-15 Koninkl Philips Electronics Nv Profilage d'une expression in vivo
JP2008545499A (ja) * 2005-06-07 2008-12-18 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 生体内発現プロファイリング
US8110407B2 (en) 2006-09-14 2012-02-07 Konica Minolta Medical & Graphic, Inc. Fluorescent semiconductor microparticle assembly, fluorescent labeling agent assembly for biological substance, and bioimaging method and biological substance analysis method using the assemblies
EP2060916A4 (fr) * 2006-09-14 2010-09-22 Konica Minolta Med & Graphic Ensemble microparticules semi-conductrices fluorescentes, ensemble agent de marquage fluorescent pour substances biologiques, et procédé de bio-imagerie et procédé d'analyse de substances biologiques au moyen de ces ensembles
EP2060916A1 (fr) * 2006-09-14 2009-05-20 Konica Minolta Medical & Graphic, Inc. Ensemble microparticules semi-conductrices fluorescentes, ensemble agent de marquage fluorescent pour substances biologiques, et procédé de bio-imagerie et procédé d'analyse de substances biologiques au moyen de ces ensembles
EP2185175A2 (fr) * 2007-08-15 2010-05-19 Yeda Research And Development Co. Ltd. Régulateurs de la mmp-9 et leurs utilisations
CN102083455A (zh) * 2007-08-15 2011-06-01 耶达研究及发展有限公司 Mmp-9的调节剂及其用途
EP2185175B1 (fr) * 2007-08-15 2013-02-13 Yeda Research and Development Co. Ltd. Régulateurs de la mmp-9 et leurs utilisations
CN102083455B (zh) * 2007-08-15 2015-01-07 耶达研究及发展有限公司 Mmp-9的调节剂及其用途
US8999332B2 (en) 2007-08-15 2015-04-07 Yeda Research And Development Co. Ltd. Regulators of MMP-9 and uses thereof

Also Published As

Publication number Publication date
EP1487343A4 (fr) 2007-03-21
ATE419536T1 (de) 2009-01-15
US20090068108A1 (en) 2009-03-12
DE60325564D1 (de) 2009-02-12
AU2003213729A1 (en) 2003-09-22
EP1487343B1 (fr) 2008-12-31
US20040023415A1 (en) 2004-02-05
CA2478083A1 (fr) 2003-09-18
EP1487343A1 (fr) 2004-12-22

Similar Documents

Publication Publication Date Title
EP1487343B1 (fr) Produits de contraste biospecifiques
Chinen et al. Nanoparticle probes for the detection of cancer biomarkers, cells, and tissues by fluorescence
Nie et al. Nanotechnology applications in cancer
Volkov Quantum dots in nanomedicine: recent trends, advances and unresolved issues
Hellebust et al. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics
Pierce et al. Optical contrast agents and imaging systems for detection and diagnosis of cancer
US8889414B2 (en) Semiconductor nanocrystal-based phagokinetic tracking
Abramczyk et al. Raman imaging in biochemical and biomedical applications. Diagnosis and treatment of breast cancer
MacLaughlin et al. Surface-enhanced Raman scattering dye-labeled Au nanoparticles for triplexed detection of leukemia and lymphoma cells and SERS flow cytometry
Gao et al. In vivo cancer targeting and imaging with semiconductor quantum dots
Sokolov et al. Optical systems for in vivo molecular imaging of cancer
Levy et al. Gold nanoparticles delivery in mammalian live cells: a critical review
JP6215902B2 (ja) 表面増強ラマン分光法（ｓｅｒｓ）活性粒子を使用するアッセイ
CN101679022A (zh) 使用表面增强拉曼纳米粒子标记物的体内肿瘤靶向和光谱检测
Sokolov et al. Molecular optical imaging of therapeutic targets of cancer
Wang et al. NIR-II imaging and sandwiched plasmonic biosensor for ultrasensitive intraoperative definition of tumor-invaded lymph nodes
Zhou et al. Quantum dot-based immunohistochemistry for pathological applications
Sukhanova et al. Fluorescent nanocrystal quantum dots as medical diagnostic tools
Feiner-Gracia et al. Advanced optical microscopy techniques for the investigation of cell-nanoparticle interactions
Nanda et al. Recent advances in biocompatible semiconductor nanocrystals for immunobiological applications
Guo et al. Modern optical techniques provide a bright outlook for cell analysis
Yunusova et al. Optical imaging of exosomes for cancer diagnosis, monitoring, and prognosis
Ghaderi Development of fluorescent nanoparticles ‘quantum dots’ for biomedical application
Prochazka et al. Medical applications of SERS
Nie et al. and Jonathan W. Simons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2478083

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003711417

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003711417

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载